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Paternal Age Effect Mutations and Selfish
Spermatogonial Selection: Causes
and Consequences for Human Disease
Anne Goriely1,* and Andrew O.M. Wilkie1,*Advanced paternal age has been associated with an increased risk
for spontaneous congenital disorders and common complex
diseases (such as some cancers, schizophrenia, and autism), but
the mechanisms that mediate this effect have been poorly under-
stood. A small group of disorders, including Apert syndrome
(caused by FGFR2mutations), achondroplasia, and thanatophoric
dysplasia (FGFR3), and Costello syndrome (HRAS), which we
collectively term ‘‘paternal age effect’’ (PAE) disorders, provides a
good model to study the biological and molecular basis of this
phenomenon. Recent evidence from direct quantification of PAE
mutations in sperm and testes suggests that the common factor
in the paternal age effect lies in the dysregulation of spermatogo-
nial cell behavior, an effect mediated molecularly through the
growth factor receptor-RAS signal transduction pathway. The
data show that PAE mutations, although arising rarely, are posi-
tively selected and expand clonally in normal testes through a
process akin to oncogenesis. This clonal expansion, which is likely
to take place in the testes of all men, leads to the relative enrich-
ment of mutant sperm over time—explaining the observed
paternal age effect associated with these disorders—and in rare
cases to the formation of testicular tumors. As regulation of RAS
and other mediators of cellular proliferation and survival is impor-
tant in many different biological contexts, for example during
tumorigenesis, organ homeostasis and neurogenesis, the conse-
quences of selfish mutations that hijack this process within the
testis are likely to extend far beyond congenital skeletal disorders
to include complex diseases, such as neurocognitive disorders
and cancer predisposition.Introduction
It has long been recognized that older parents are at
increased risk of having children with genetic disorders.
Much work has gone into studying congenital anomalies
in the offspring of aging mothers, and the best docu-
mented example of a strong maternal age effect occurs in
Down syndrome (trisomy 21).1 However, growing evi-
dence suggests that, independently of maternal age, the
progeny of older fathers are more susceptible to a wide
range of conditions, including spontaneous dominant dis-
orders,2 congenital anomalies,3 childhood cancers,4 acute
lymphoblastic leukemia,5 breast cancer,6 increased telo-
mere length,7 autism,8 schizophrenia,9 bipolar disorder,10
and reduced neurocognitive abilities in childhood and
infancy.11 Although the association between advanced
paternal age and disease risk is not always consistent or
reproducible,12,13 it is clear that it has become a concern,1Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX
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The Americaas witnessed by the precautionary measures taken for
sperm donation in the case of assisted conception, for
which it is now commonly advised to limit the age of
donors to below 40 years.14 Yet, there is a notable lack of
understanding of the mechanisms involved or even
a general consensus on how to define what constitutes
advanced paternal age.14,15 It is apparent that the average
paternal age at conception is subject to demographic vari-
ation and fluctuates considerably for different years of
birth or countries.15 In England and Wales, for instance,
it has increased steadily from 29.06 years in the mid-
1970s to 32.75 years by 2008, and today over one-third
of children are born to fathers over the age of 35 years
(England and Wales Birth Census data series FM1). Given
that this trend is also observed in many other developed
countries, it would be timely to re-evaluate the impact
that paternal age has on genetic risks and predict its effects
both on individual risk and on public health. However,
this is hampered by lack of understanding of the mecha-
nisms involved and the extent of the effects—which are
likely to vary considerably for different disorders.
Although in some cases the evidence for an association
with advanced paternal age is ill-defined or controversial,
the situation is very different for a small group of congen-
ital disorders, which we call ‘‘paternal age effect’’ (PAE)
disorders and for which work performed over the last
decade is reaching a consensus that allows a clearer picture
of the biological mechanisms associated with some
paternal age effects. The best known examples of PAE
disorders involve specific point mutations in fibroblast
growth factor receptor genes, FGFR2 (mutations of which
cause Apert [MIM 101200], Crouzon [MIM 123500], and
Pfeiffer[(MIM 101600] syndromes) and its paralog, FGFR3
(mutations of which cause achondroplasia [MIM 100800]
and thanatophoric dysplasia [MIM 187601 and 187602],
hypochondroplasia [MIM 146000], andMuenke syndrome
[MIM 602849]). These disorders occur spontaneously with
a remarkably high apparent rate, reaching 1 in 30,000
births for achondroplasia,16,17 and are associated with an
increased paternal age, relative to the general popula-
tion.2,18–21 Additionally, mutations in RET (causing
multiple endocrine neoplasia types 2A22 [MIM 171400]
and 2B23 [MIM 162300]), PTPN11 (encoding SHP2 and
causing Noonan syndrome24 [MIM 163950]), and HRAS3 9DS, UK
x.ac.uk (A.O.M.W.)
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(Costello syndrome25–27 [MIM 218040]) are also associated
with advanced paternal age, allowing a better under-
standing of the mechanisms involved in this process.
Indeed there are striking parallels between all these PAE
disorders that extend beyond the epidemiological observa-
tions of a paternal age effect: all are caused by a small
number of dominantly-acting point mutations in key
developmental regulators, which cluster within the growth
factor receptor-RAS signaling pathway; moreover, the
causative point mutations originate almost exclusively
from the unaffected fathers, indicating that the original
mutational events are taking place during spermatogenesis.
In turn, these observations have led to efforts to quantify
these mutations directly in the sperm and testes of men of
different ages, which has now been accomplished for
a handful of PAE mutations. The picture emerging from
these technically challenging studies is that the paternal
age effect associatedwith these conditions canbe explained
by a mechanism, which we term ‘‘selfish selection,’’
whereby rare spermatogonial cells bearing mutations are
positively selected, leading to their progressive clonal
expansion. This process of clonal expansion in the testis,
which is associated with testicular tumors in rare cases, is
likely to be universal and to affect all men as they age.
In the first half of this review, we will examine the
evidence gathered from the small number of canonical
PAE disorders. We will describe the characteristic features
of the FGFR2 and FGFR3 mutations and their cognate
disorders to show how these syndromes illustrate the
mechanisms and principles involved in the paternal age
effect. We will then collate information on mutations
in the other PAE genes, describing how they provide
important information on the molecular pathways (in
the case of the RASopathies such as Costello and Noonan
syndromes) and the biological mechanisms involved
(in the case of RET-associated disorders). Later, we will
consider the possibility that selfish selection is a common
mechanism operating during male gametogenesis that has
potentially far-reaching consequences for genetic varia-
tion, disease, and evolution.Wewill argue that the contrib-
uting mutational processes are likely not limited to single-
base-pair substitutions in protein-coding genes but include
regulatory mutations and copy-number variations and
that the phenotypic consequences extend beyond certain
rare monogenic congenital disorders to include common
complex diseases. Recently acquired rare mutations have
been postulated to contribute to some of the ‘‘missing
heritability’’ that has been associated with complex disor-
ders.28 As selfish selection is predicted to generate recur-
rent functional alleles acting on pleiotropic signaling,
such mechanisms might contribute significantly to the
mutational burden associated with complex phenotypes.
Spectrum and Characteristics of PAE Mutations
and Associated Disorders
We define PAE disorders as a small class of syndromes
caused by spontaneous dominant heterozygous mutations176 The American Journal of Human Genetics 90, 175–200, Februarythat present with a triad of unusual features comprising (1)
an extreme bias in paternal origin of mutations (defined as
the ratio of male-to-female mutations, a > 20), (2) a strong
paternal age effect (i.e., the fathers of affected children are
on average more than 2 years older than the matched
general population), and (3) a high apparent germline
mutation rate (>106 for particular individual mutations).
Nine autosomal-dominant disorders (Apert, Crouzon,
Pfeiffer, and Muenke syndromes; achondroplasia; Costello
andNoonan syndromes; andmultiple endocrine neoplasia
types 2A and 2B), corresponding to specific point muta-
tions within five genes (FGFR2, FGFR3, HRAS, PTPN11,
and RET) can be identified that strictly fulfill all three
criteria (Table 1).
For historical and practical reasons, the best studied
examples of PAE disorders are Apert syndrome, character-
ized by craniosynostosis (premature fusion of the cranial
sutures) and severe syndactyly of both hands and feet,
and achondroplasia, the most common cause of short-
limbed dwarfism. Both conditions are fully penetrant
and clinically homogeneous monogenic disorders that
allow complete ascertainment and exhibit a straightfor-
ward genotype-phenotype correlation: about 99% of
individuals with Apert syndrome carry either of two trans-
versions (c.755C>G or c.758C>G), encoding substitutions
in two adjacent amino acids (p.Ser252Trp or p.Pro253Arg,
respectively) located within the extracellular region of the
receptor tyrosine kinase protein fibroblast growth factor
receptor-2 (FGFR2),29 whereas substitutions at a single
nucleotide (encoding a p.Gly380Arg mutant protein) in
its paralog FGFR3 cause more than 95% of achondroplasia
cases;30 in the FGFR3 c.1138G>A transition outweighs the
c.1138G>C transversion by a factor of 35-fold.30,31 Among
the other FGFR-associated disorders belonging to the PAE
class, Crouzon and Pfeiffer syndromes are clinically over-
lapping conditions typically caused by any of more than
50 specific activating point mutations in FGFR2; craniosy-
nostosis occurs as in Apert syndrome, but limb abnor-
malities are milder.32 A single c.749C>G transversion in
FGFR3 (resulting in a p.Pro250Arg substitution equivalent
to the FGFR2 Apert-causing p.Pro253Arg) is responsible for
all cases of Muenke syndrome, the most common genetic
cause of coronal craniosynostosis, and makes this disorder
allelic to, but clinically distinct from, achondroplasia.33
Of the other PAE disorders, Costello and Noonan syn-
dromes are part of a larger family of neuro-cardio-facial-
cutaneous syndromes or RASopathies, the latter term
describing their collective dysregulation of the RAS
signaling pathway.34 Patients with these conditions
present with variable combinations of distinctive craniofa-
cial features; short stature; failure to thrive; developmental
delay; and skin, cardiac, and skeletal abnormalities. A few
Noonan syndrome cases have also been associated with
craniosynostosis.35 Up to 90% of Costello syndrome
patients harbor the c.34G>A transition in HRAS (encoding
p.Gly12Ser) at a well-known mutation hotspot in tu-
morigenesis, whereas about half of Noonan syndrome10, 2012
mutations are detected within the PTPN11 gene (encoding
SHP2-containing tyrosine phosphatase). However, specific
point mutations in other components of the RAS pathway
(i.e., BRAF, CBL, CRAF, KRAS, NRAS, SHOC2, and SOS1)
have also been described in Noonan patients.34,36
The last two PAE disorders, multiple endocrine neoplasia
types 2A (Men2A) and 2B (Men2B), are caused by allelic
mutations within the RET receptor tyrosine kinase and
are complex syndromes of multiple endocrine neoplasms,
characteristically including medullary thyroid carcinoma
(MTC). Men2A might also be associated with pheochro-
mocytoma and parathyroid adenomas, whereas in
Men2B, the onset can be congenital with marfanoid
habitus and mucosal neuromas (involving lips, tongue,
eyebrows, and intestine) as well as skin hyperpigmentation
and cafe´-au-lait spots on the hands and feet. Although
most cases of Men2A are caused by a handful of activating
mutations at crucial cysteine residues located in the extra-
cellular portion of RET (i.e., p.Cys609, p.Cys611,
p.Cys618, p.Cys620, p.Cys630, and p.Cys634), Men2B is
a more aggressive syndrome mostly caused by a single
p.Met918Thr (c.2753T>C) substitution at a residue
located in the catalytic core of the tyrosine kinase
domain.37
Although each PAE syndrome is a clearly distinct and
well-defined complex pathological entity, there is a notice-
able phenotypic overlap between them; all involve combi-
nations of congenital skeletal abnormalities (for example
craniosynostosis, hypertelorism, syndactyly, coarse facies,
marfanoid habitus, or short stature), in some cases associ-
ated with developmental delay, cardiac malformation,
skin hyperpigmentation, and cancer predisposition. These
complex phenotypes highlight the pleiotropic role played
by the PAE genes during development, whereas the clinical
overlap points to the fact that these genes are required in
common cellular contexts in shared molecular pathways.
Several closely related conditions, including thanato-
phoric dysplasia (caused by FGFR3 mutations) and car-
dio-facio-cutaneous syndrome ([MIM 115150] associated
with BRAF, MAP2K1, and MAP2K2mutations) that exhibit
a large phenotypic and molecular overlap with the disor-
ders described above, are likely to belong to the PAE class,
although some of the experimental evidence for meeting
all three PAE criteria is still lacking (Table 2). Significantly,
at a biochemical level, all PAE mutations confer gain-of-
function properties to the encoded mutant proteins
through a wide diversity of mechanisms (Table S1, avail-
able online).
Paternal Origin of Mutations, Paternal Age Effect,
and High Rate of Spontaneous Mutations
Each of the properties used to define PAE mutations will
be considered separately, and we will discuss why they
are relevant to our understanding of paternal age effects.
We will argue that although a paternal bias in mutation
origin is observed for many spontaneous dominant disor-
ders, and likely results from a universal replication-basedThe Americaprocess that generates DNA copy errors during male game-
togenesis, the extreme paternal bias observed for PAE
mutations is caused by the distinct phenomenon of clonal
expansion of spermatogonial cells expressing proteins
with gain-of-function properties. This selective process
taking place in the testis leads to the relative enrichment
of mutant sperm over the course of time, which accounts
for the epidemiological paternal age effect and the high
de novo birth rates associated with the PAE disorders.
Gender Bias in the Origin of Spontaneous Mutations
Studies of mutations in humans have long established that
there is a gender-specific signature in the origin of different
types of genetic alterations. Although chromosomal
nondisjunctions originate mainly in the female germ-
line1 and large genomic rearrangements might show either
a male or female bias in origin, the majority of point muta-
tions and small deletions or insertions tend to be paternal
in origin. This gender bias is generally explained by funda-
mental differences in germ cell biology in the female and
male lineages.38,39 By the time of birth, germ cells in the
developing ovary have already completed their prolifera-
tive phase; because all postnatal phases of germ cell devel-
opment are meiotic, maternal mutagenic events involve
mostly recombination-related mechanisms. By contrast,
spermatogenesis requires regular mitotic divisions of sper-
matogonial stem cells (SSCs) throughout male reproduc-
tive life. From puberty onward, cells in the SSC lineage
replicate at a rate of 23 divisions per year (in synchrony
with the epithelial cycle, i.e., every 16 days in humans)
to produce different types of cells; some maintain the
stem cell population, whereas others follow a differentia-
tive pathway and produce mature sperm after approxi-
mately five further divisions. Because this process involves
recurrent rounds of DNA replications, random copy-error
mutational events are predicted to arise mainly in the
male germline,40 explaining the elevated male-to-female
mutation ratio (a) of between 2 and 7, which is observed
for themajority of spontaneous point mutations and small
deletions41,42 (Table 3). In contrast to this general situa-
tion, PAE mutations show much more extreme bias in
mutation origin with values of a > 20 (Table 1).
Paternal Age Effect
For most spontaneous dominant disorders, despite the
expectation of the copy-error hypothesis,39 epidemiolog-
ical data concur that the bias in paternally originating
mutations is not associated with a marked paternal age
effect, showing that paternal bias and paternal age effect
are not equivalent and can be dissociated. The paternal
age effect is an epidemiological concept describing the
fact that some spontaneous disorders tend to arise more
frequently in the progeny of older men. As early as 1912,
Wilhelm Weinberg, while studying sporadic cases of
achondroplasia, noted a higher incidence of the disease
in the last-born children of a sibship.43 In 1955, Lionel
Penrose suggested that rather than birth order itself, then Journal of Human Genetics 90, 175–200, February 10, 2012 177
Table 1. PAE Genes and Associated Disorders
Gene
Symbol Gene
DNA
Mutation a
(Amino
Acid)b
Clinical
Disorder
OMIM
Reference
Number
Mode of
Trans-
mission
Mutation
Mecha-
nism
Infor-
mative
Paternal
Muta-
tions
Infor-
mative
Maternal
Muta-
tions
Paternal
Origin
Average
Paternal
Agec
(Years)
Average
Excess in
Paternal
Aged
(Years)
Estimated
Birth
Prevalence
for New
Mutations
Sperm
Study
Cancer
Predis-
position
in
Patients?
Reported
as Somatic
Mutation?e References
FGFR2 fibroblast
growth
factor
receptor 2
c.755C>G
(p.Ser252Trp)
c.758C>G
(p.Pro253Arg)
Apert
syndrome
101200 autosomal
dominant
GOF 75 0 100% 32.5; 34.1 2.5
(1.7–3.2)
~1/65,000 yes not
reported
endometrial
cancer
Cohen et al.18,
Tolarova
et al.19,
Moloney
et al.45,
Wilkie et al.55,
Goriely
et al.56,
Yoon et al.58,
Hansen161
FGFR2 fibroblast
growth
factor
receptor 2
>50 different
mutations,
11 used for
paternal
origin
studies
Crouzon/
Pfeiffer
syndrome
123500/
101600
autosomal
dominant
GOF 22 0 100% 34.5 4.1 ~1/50,000–
1/100,000
yes,
c.755C
> T
not
reported
lung
stomach
endometrial
cancer
Goriely
et al.56,
Glaser
et al162
FGFR3 fibroblast
growth
factor
receptor 3
c.1138G>A
(p.Gly380Arg)
c.1138G>C
(p.Gly380Arg)
achon-
droplasia
100800 autosomal
dominant
GOF 40 0 100% 35.9; 36.3;
37.2
7.1
(4.6–9.6)
~1/30,000 yes not
reported
bladder
cancer
Orioli
et al.16,20,
Waller
et al.17,
Tiemann-
Boege et al.53,
Wilkin
et al.163
FGFR3 fibroblast
growth
factor
receptor 3
749C>G
(p.Pro250Arg)
Muenke
syndrome
602849 autosomal
dominant
GOF 10 0 100% 35.1 4.1 ~1/130,000 no not
reported
no Rannan-Eliya
et al.21
HRAS Harvey rat
sarcoma
viral
oncogene
homolog
various
mutations
in a few
codons, most
commonly
c.34G>A
(p.Gly12Ser)
Costello
syndrome
218040 autosomal
dominant
GOF 43 2 96% 37.3; 38.0;
36.2
5.5
(4–7)
raref ~1/
300,000
no bladder
rhabdo-
myosarcoma
many
cancer
types
Sol-Church
et al.25,
Zampino
et al26,
Schulz et al.27,
Søvik et al.164,
Gripp et al.165
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Table 1. Continued
Gene
Symbol Gene
DNA
Mutation a
(Amino
Acid)b
Clinical
Disorder
OMIM
Reference
Number
Mode of
Trans-
mission
Mutation
Mecha-
nism
Infor-
mative
Paternal
Muta-
tions
Infor-
mative
Maternal
Muta-
tions
Paternal
Origin
Average
Paternal
Agec
(Years)
Average
Excess in
Paternal
Aged
(Years)
Estimated
Birth
Prevalence
for New
Mutations
Sperm
Study
Cancer
Predis-
position
in
Patients?
Reported
as Somatic
Mutation?e References
PTPN11 protein
tyrosine
phosphatase,
nonreceptor
type 11
(encoding
SHP2)
many
mutations,
5 used for
paternal
origin
studies
Noonan
syndrome
163950 autosomal
dominant
GOF 14 0 100% 35.6 6.1 ~1/10,000f
caused by
various
mutations
no juvenile
myelomono-
cytic
leukemia
(JMML)
JMML and
other
hematologic
malignancies
Tartaglia
et al.24
RET ret proto-
oncogene
various
mutations
clustering
at 6 cysteine
codons, most
commonly
at p.Cys634
multiple
endocrine
neoplasia
type 2A
171400 autosomal
dominant
GOF 11 0 100% 39.3 8.7 ~1/70,000 no medullary
thyroid
carcinoma
(MTC)
thyroid
cancer
Schuffenecker
et al.22,
Wohllk
et al.166,
Mulligan
et al.167
RET ret proto-
oncogene
c.2753T>C
(p.Met918Thr)
multiple
endocrine
neoplasia
type 2B
162300 autosomal
dominant
GOF 25 1 96% 33 3.1 ~1/150,000 no medullary
thyroid
carcinoma
(MTC)
thyroid
cancer
Carlson
et al.23,
Kitamura
et al.168
GOF is used as an abbreviation for gain-of-function.
a The Reference sequences (RefSeq) are: NM_000141 for FGFR2, NM_000142 for FGFR3, NM_001130442 for HRAS, NM_002834 for PTPN11 and NM_020630 for RET.
b The RefSeq are: NP_000132.3 for FGFR2, NP_000133.1 for FGFR3, NP_001123914.1 for HRAS, NP_002825.3 for SHP2, NP_066124.1 for RET (long isoform).
c The different ages represent data obtained from independent studies. To establish statistical significance, these data are compared to matched population data to take into account the natural variation in average paternal
age for different countries and years of birth.
d The data given represent the average paternal age excess obtained from different studies (with data range given in brackets).
e Reference: COSMIC database.
f Collectively RASopathies have an incidence estimated to be 1/2,000 to 1/5,000 births.169 However, because of the large diagnostic overlap, precise epidemiological data on the prevalence of each mutation are scarce.
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Table 2. Disorders Sharing Several Features with PAE Disorders but for which Some Data Are Still Missing
Gene
symbol Gene
DNA
Mutation
(Amino
Acid)a
Clinical
Disorder
OMIM
Reference
Number
Mode of
Trans-
mission
Mutation
Mecha-
nism
Infor-
mative
Paternal
Muta-
tions
Infor-
mative
Maternal
Muta-
tions
Paternal
Origin
Percentage
Average
Paternal
Ageb
(Years)
Average
Excess in
Paternal
Agec
(Years)
Estimated
Birth
Prevalence
for New
Mutations
Sperm
Study
Cancer
Predis-
position in
Patients?
Reported
as Somatic
mutation?d References
BRAF v-RAF
murine
sarcoma
viral
oncogene
homolog-B1
various
mutations
cardio-facio-
cutaneous
syndrome
115150 autosomal
dominant
GOF n/a n/a n/a 35.8 4.8 raree
~1/200,000–
1/300,000
no not
reported
many
cancer
types
Schulz
et al.27
MAP2K1
MAP2K2
mitogen-
activated
protein
kinase
kinase 1/2
various
mutations
cardio-facio-
cutaneous
syndrome
115150 autosomal
dominant
GOF n/a n/a n/a melanoma Schulz
et al.27
FGFR3 fibroblast
growth
factor
receptor 3
mutations at
six residues,
most
commonly
c.742C>T
(p.Arg248Cys)
thanatophoric
dysplasia
type I
187600 autosomal
dominant
GOF n/a n/a n/a 33.6; 36.41 5.1
(2.5–7.6)
~1/60,000 no n.a. bladder,
skin,
myeloma
Orioli
et al.20,
Goriely
et al.62,
Tavormina
et al.63
FGFR3 fibroblast
growth
factor
receptor 3
c.1948A>G
(p.Lys650Glu)
thanatophoric
dysplasia
type II
187601 autosomal
dominant
GOF n/a n/a n/a bladder,
skin, testis
Orioli
et al.20,
Goriely
et al.62,
Tavormina
et al.63
The following abbreviations are used: GOF, gain-of-function; n/a, not available; n.a., not applicable (TD is a neonatal lethal disorder).
a The RefSeq used for numbering are given in footnotes a and b of Table 1.
b The different ages represent data obtained from independent studies. To establish statistical significance, these data are compared to matched population data to take into account the natural variation in average paternal
age for different countries and years of birth.
c The data given represent the average paternal age excess obtained from different studies (with data range given in brackets).
d Reference: COSMIC database.
e Collectively RASopathies have an incidence estimated to be 1/2,000 to 1/5,000 births.169 However, because of the large diagnostic overlap, precise epidemiological data on the prevalence of each mutation are scarce.
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Table 3. Examples of Dominant Disorders Associated with Biased Paternal Origin of Mutations but No Significant Paternal Age Effect
Clinical Disorder
OMIM
Reference
Number
Gene
Symbol
Number of
Mutations
Reported
Mode of
Transmission
Mutation
Mechanism
Informative
Paternal
Mutations
Informative
Maternal
Mutations
Paternal
Origin
Average
Paternal
Age (Years) References
Alexander disease 203450 GFAP ~35, two
recurrent
autosomal
dominant
structural
alteration
24 4 86% 32.3 NS Li et al.170
CHARGE (coloboma,
heart anomaly
choanal atresia,
retardation, genital
and ear anomalies)
214800 CHD7 >200 autosomal
dominant
LOF
haploinsufficency
12 1 93% 32.92 NS(a) Pauli et al.171
Craniofrontonasal
syndrome
304110 EFNB1 >100 X linked
dominant
LOF cellular
interference
15 2 88% 32.1 NS Twigg et al.172
Dravet syndrome
or severe
myoclonic epilepsy
of infancy
607208 SCN1A >400 autosomal
dominant
LOF
haploinsufficency
43 13 77% 33.4 NS Heron et al.173,
Sun et al.174
Rett syndrome 312750 MECP2 >300, eight
recurrent
X linked
dominant
LOF(b) 53 5 91% 31.3 NS Trappe et al.175,
Girard et al.176,
Zhu et al.177
Townes-Brocks
syndrome
107480 SALL1 >40 autosomal
dominant
LOF
haploinsufficency
14 2 88% 29.9 NS Bo¨hm et al.178
Treacher Collins
syndrome
154500 TCOF1 >120 autosomal
dominant
LOF
haploinsufficency
7 3 70% 27.8 NS Splendore et al.179
The following abbreviations are used: NS, not significantly different from control population on statistical testing; LOF, loss-of-function; GOF, gain-of-function.
a Note that in this study paternal age is given for the whole cohort rather than for paternally derived mutations only.
b Rett syndrome mostly affects females. Because of random X inactivation, the clinical presentation of Rett syndrome shows considerable heterogeneity.
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key risk factor associated with sporadic achondroplasia was
advanced paternal age.40 Although the notion of paternal
age effect is easy to grasp, confounding with correlated
maternal age made its study problematic in the premolec-
ular era because the parental origin of each individual
mutation could not be deduced.
The concept of paternal age effect received further recog-
nition after the comprehensive study byRisch et al.,2which
systematically analyzed the distribution of parental ages for
spontaneous cases of 17 different autosomal-dominant
disorders. Among these, the authors compared parental
ageprofiles to the agedistribution in the general population
(obtained from year-matched population census data) for
seven disorders and derived an observed/expected (O/E)
ratio that gave a directmeasurement of the age-specific inci-
dence excess for each disorder. This approach suggested
that the disorders fell into two main categories. Some
syndromes showed no, or a small, linear increase with
maternal and paternal ages; whereas for others, including
Apert, Pfeiffer, and Crouzon syndromes and achondro-
plasia, the age excess was more pronounced and the rela-
tionship with paternal age was nonlinear (proposed to be
exponential), rising sharply as the father’s age increased
even after correction for maternal age. Although these
data singled out the paternal age as the major risk factor
in this latter group of genetic disorders, the authors sug-
gested that maternal age provided an independent but
lesser contribution. Because we now know (from parent-
of-origin studies) that maternal age is irrelevant to PAE
disorders, this illustrates the inherent ambiguity arising
from epidemiological studies when unsupported bymolec-
ular data. Moreover, because themagnitude of paternal age
effects is of similar order (~2–7 years) to natural variation in
average paternal age attributable to place (country), year of
birth, and whether the birth occurred within or outside
marriage, case observations need to be carefully compared
to control data sets matched for all these variables—for
which information is often difficult to obtain.
The traditional explanation for these paternal age effects
involved a model of age-dependent accumulation of
recurrent mutations taking place within localized hyper-
mutable DNA hotspots (the copy-error hypothesis).39,40
However, it was noted that a simple additive model of
replication errors could not explain either the magnitude
of some of the most extreme paternal age effects or the
nonlinear shape of the observed epidemiological
data.2,39,44 To account for this, it was suggested that other
age-dependent factors, such as reduced DNA replication
fidelity, inefficiency of repair mechanisms, or repeated
mutagenic exposures would have to contribute to the accu-
mulation of copy errors.39
Today, molecular characterization of the causative muta-
tions allows refined documentation of paternal age effects
by including only those cases shown to have a paternal
origin, most commonly by determining the phase of
the mutation with respect to nearby polymorphisms or
haplotypes segregating in parent-child trios.45 This182 The American Journal of Human Genetics 90, 175–200, Februaryapproach has established that the disorders associated
with strong paternal age effects (~2–7 years) also exhibit
an extreme paternal bias in the origin of the causative
mutations (Table 1). The bias observed for PAE mutations
(a > 20) is more pronounced than would be expected
from gender differences in the number of germ cell divi-
sions.
High Germline Mutation Rate
The third defining characteristic of PAE disorders is the
high absolute rates observed for specific de novo point
mutations (Table 1 and Figure 1). The average background
rate of spontaneous point mutations in the human
genome, estimated by several different methods, including
recent direct transgenerational measurement of muta-
tional load, is ~1.13 108 (range: 0.4 163 108, depend-
ing on the type of mutation) per nucleotide per genera-
tion46–52 (Figure 1A). Given the very narrow mutational
spectrum of several sporadic PAE disorders, it can be calcu-
lated that the causative mutations comprise the most
frequent germline nucleotide substitutions in the entire
genome, occurring at levels up to 1,000-fold higher than
the background nucleotide substitution frequencies (Table
1 and Figure 1B). Simplemechanisms of mutation accumu-
lation, such as copy error, are difficult to reconcile with the
very high a values and absolute rates of spontaneous PAE
mutations, casting doubt on the notion that copy errors
at localized mutation hotspots are the sole driver of this
process. Experimental study of these mutations directly
in sperm and testes has provided insights into their mech-
anisms of origin.
Direct Quantification of FGFR2- and FGFR3-
Associated PAE Mutations in Sperm and Testes
The unusual characteristics of the Apert and achondro-
plasia point mutations have led several groups to develop
methods to identify these mutations directly in sperm
and testes of normal individuals. The sperm studies are
a powerful complement to the epidemiological analysis
of disease prevalence and allow direct estimates of muta-
tion levels at specific positions within the genome.
Another advantage of this approach is the ability to study
a wider age range and, in particular, to assess the paternal
age effect at older ages, when there are too few paternities
for epidemiological data to be accurate.
The development of sensitive and reproducible methods
to assay these nucleotide substitutions constitutes a major
technical challenge. The main problem lies in the extreme
rarity of the mutations to study, which, on the basis of
observed birth prevalence of the cognate disorders, are ex-
pected to be present at levels around 1 in 30,000 to 1 in
100,000 at best (Figure 1B). At such low levels, the detec-
tion of single-nucleotide substitutions via direct PCR
amplification is not feasible because several million
genome copies are necessary to isolate only a few mutant
molecules. For example, at a mutation level of 105,
10 mg of human genomic DNA—typically more than10, 2012
Figure 1. Rate of Germline Mutations in the Human Genome on a Logarithmic Scale
(A) Background rate of nucleotide substitution quantified by direct measurements of transgenerational mutational load48,50,52 (unfilled
inverted triangles in dark gray box) and indirect estimates (lighter gray box) for all substitutions (inverted triangles), transitions at CpG
dinucleotides (squares), transversions at CpG dinucleotides (circles), transitions at non-CpG dinucleotides (diamonds), and transver-
sions at non-CpG dinucleotides (triangles). Data source indicated by symbol shading as follows: black,46 gray,47 and white.49
(B) Estimated birth prevalence for de novo mutations in two PAE syndromes (green box). Apert syndrome FGFR2 mutations caused by
c.755C>G transversion at a CpG dinucleotide account for 66% of cases (red circle) and mutations caused by c.758C>G transversion at
a non-CpG dinucleotide for 33% of cases (red triangle). Achondroplasia FGFR3 mutations caused by c.1138G>A transition or
c.1138G>C transversion at a CpG dinucleotide are marked by the green square and circle, respectively. Note that these figures assume
that all mutations are paternal in origin.
(C) Direct measurements of mutation levels in human sperm at specific locations in the genome. Symbols for each mutation (square,
circle, diamond, and triangle) refer to mutation types as in (A). Top blue boxes show average levels for the FGFR2 c.752–755 positions
(encompassing codons p.Arg251 and p.Ser252) measured by RED/PCR/pyrosequencing in the sperm of 99 healthy men. The strongly
activating c.755C>G (p.Ser252Trp) Apert transversion (red circle in dark blue box) and the c.755C>T (p.Ser252Leu) transition (yellow
square in dark blue box) are associated with gain-of-function (GOF) properties; these two substitutions are found at significantly higher
levels in sperm than any of the ten othermutations encoding silent or loss-of-function (LOF)mutations (light blue box). The average age
of the sperm donors was 37.4 years.56,57 Middle blue box shows average levels of the two Apert mutations measured in the sperm of
323 healthy men by Bi-PAP-A. The average age of the sperm donors was 38.7 years.58 Note that the very similar estimate for the
FGFR2 mutation c.755C>G (red circles) was obtained by different methods. Prevalence in sperm exceeds birth prevalence (B) because
sperm donors were older on average than the population of fathers. Bottom blue boxes show average levels at the FGFR3 codon
p.Lys650 in the sperm of 78men via RED/PCR/massively parallel sequencing. The substitutions encoding proteins with gain-of-function
properties (dark blue box), and in particular the c.1948A>G transition (p.Lys650Glu, causing TDII, green diamond), are found at higher
levels in sperm than the changes associated with silent/loss-of-function substitutions (light blue box). The average age of the sperm
donors was 40.2 years.62100-fold in excess of the usual input for a single PCR reac-
tion—corresponds to three million copies of the haploid
genome and would therefore contain only ~30 mutant
molecules. In addition, the potential impact of the false-
positive rate caused by in vitro PCR-induced copy errors,
oxidative stress-induced mutations (for example, those
arising during DNA extraction), or inadvertent contamina-
tion require careful consideration in the experimental
design. Partly for these reasons, two early papers, on
measurement of the achondroplasia53 and the Apert54The Americamutations are, in our opinion, subject to technical or inter-
pretational flaws that call into question the conclusions of
these studies. These issues have been discussed previ-
ously55 and hence are not considered further here.
In 2003, our group developed a sensitive and reproduc-
ible assay for the most common Apert mutation
(c.755C>G in FGFR2).56 This approach involved a combi-
nation of restriction enzyme digestion ([RED] specifically
targeting and digesting away the large excess of wild-type
sequences around the position of interest) with PCRn Journal of Human Genetics 90, 175–200, February 10, 2012 183
(RED/PCR) to enrich for mutant sequences, and pyrose-
quencing technology to quantify the resulting complex
mixture of nucleotides. Measurements of this C>G trans-
version in 99 healthy men revealed elevated levels
(average: 2.3 3 105; range: < 106  1.6 3 104) in the
sperm of most men (Figure 1C) and a significant positive
correlation (r ¼ 0.39) with age; by contrast, the mutation
levels measured in blood DNA from 11 individuals were
much lower (an average of 0.283 106, i.e., below the limit
of accurate detection) and did not increase with the
donor’s age. The levels of mutation measured in sperm
accounted for the reported birth prevalence of Apert
patients and the age increase mirrored the epidemiological
observation of the paternal age effect described for Apert
syndrome.56 Mutation levels in the sperm of six men
who had fathered a child with the c.755C>G Apert muta-
tion were within the range of values observed for controls
of similar age, suggesting that these men were sampled
from the general population and that their risk of fathering
another affected child was extremely low.56
The RED/PCR approach enabled quantification of other
mutations occurring around position c.755 of FGFR2,
which revealed a surprising result. Another substitution,
c.755C>T, encoding a p.Ser252Leu change that has been
described occasionally in patients with mild Crouzon
syndrome, was also present at unexpectedly high frequen-
cies (on average only 1.6-fold lower than the c.755C>G
levels) in sperm.57 This effect was not observed for
c.755C>A (which encodes a change to a stop codon at
position p.252) or for any of the nine nucleotide substitu-
tions involving changes at FGFR2 positions c.752–754
(Figure 1C).57 Key evidence was also provided by a phasing
assay that exploited a single-nucleotide polymorphism
(SNP) located 118 bp from the c.755C nucleotide (Figures
2A and 2B). Instead of the c.755C>G mutations being
distributed roughly equally on the two chromosomes in
men heterozygous for the SNP—as would be predicted
from a model of mutation accumulation at a recurrent
hotspot—even in sperm with high mutation levels (corre-
sponding to more than 1,000-fold excess over back-
ground), the majority of mutations were usually present
on one or the other allele. This skewing effect was much
more pronounced for the c.755C>G than the less abun-
dant c.755C>T mutation, an observation incompatible
with a neutral model of mutation accumulation, in which
the more prevalent mutation is expected always to exhibit
less skewing56 (Figure 2B). Collectively, these findings led
us to propose56,57 that, rather than resulting from accumu-
lation of multiple independent replication errors during
spermatogenesis, the originating FGFR2mutational events
in Apert syndrome are rare, but once they occur, the muta-
tions become enriched because of a selective advantage
conferred by the mutant FGFR2 protein, leading to clonal
expansion of the mutant SSC (Figure 2A). This process in
turn results in a relative enrichment of mutant sperm
over time (Figure 2B), accounting for the observed paternal
age effect and the high birth rate associated with this184 The American Journal of Human Genetics 90, 175–200, Februaryspecific mutation. To distinguish this mechanism from
the previously proposed copy-error process involving the
simple accumulation of mutational hits over time, we
named this mechanism protein-driven selfish selection.57
The main conclusions of these studies were confirmed
and extended by independent work that exploited a
different method of mutation detection involving a sensi-
tive allele-specific PCR assay termed bidirectional pyro-
phosphorolysis-activated polymerization allele-specific
amplification (Bi-PAP-A).58 The levels of both FGFR2muta-
tions associated with Apert syndrome (c.755C>G and
c.758C>G) were estimated in the sperm of a large cohort
of men and showed a similar average level and age effect
for the c.755C>G mutation (2.4 3 105; range: < 106
 7.25 3 104) to that previously reported56 (Figure 1C).
Although the technique used was not able to partition
mutations on the two FGFR2 alleles, the same group used
their Bi-PAP-A assay to quantify the spatial distribution
of mutations within whole human testes dissected into
~200 pieces. This demonstrated a small number of local-
ized mutation foci (0–~8 per testis) exhibiting elevated
mutation levels, up to 6% of the haploid genome in indi-
vidual testicular pieces; rather than being distributed
randomly at low level over the whole testis (as would be ex-
pected from a copy-error model), 95% of the Apert muta-
tions clustered within fewer than 5% of the testis pieces
and accounted for the mutation load present in epidid-
ymal sperm DNA from the same individual. Furthermore,
mathematical modeling provided additional evidence for
a mechanism involving infrequent mutational events fol-
lowed by a process of localized clonal expansion of mutant
SSC with weak selective advantage (~0.01 per cell genera-
tion).59,60 A study of the FGFR3 achondroplasia mutation
in testes,61 although relying on the same protocol and
hence subject to the same technical limitations as earlier
work in sperm,53 obtained a similar picture of localized
mutational clusters in testicular biopsies of older men.
Although experimental confirmation is awaited, we antic-
ipate that the FGFR3 achondroplasia mutation is likely to
show similar behavior to the Apert mutation in sperm
(Figure 2C). This hypothesis is supported by another sperm
study62 targeting an allelic FGFR3 mutation (c.1948A>G
[encoding p.Lys650Glu]) associated with the germline
disorder thanatophoric dysplasia (TD) type II,63 a severe
neonatal lethal skeletal condition that shares many diag-
nostic features with the other PAE disorders (Table 2 and
Figure 1C) and will be reviewed in the next section.
The emerging consensus is that the major determinant
of the paternal age effect is not the hypermutability of
specific nucleotides located at genomic hotspots but
rather the effect of expressing the resulting mutant
protein in SSC, which is associated with positive selection
resulting in localized clonal expansion. Certainly, initial
copy errors have to take place during spermatogenesis for
this process to occur; therefore, the endogenousmutability
and local sequence context64 of a nucleotide contribute
to this process. As experimental data have shown that the10, 2012
Figure 2. Relative Prevalence of FGFR2 and FGFR3 Mutations Explained by Combined Effects of Copy Error, at the DNA level, and
Selfish Selection, at the Protein Level, in SSC
(A) Mutational events taking place at FGFR2 position c.755C. Each pair of lines with gray boxes denotes the two FGFR alleles (box repre-
sents the exon and lines represent the intron. Asterisks in (A) represent a SNP located in the intron upstream of FGFR2 position c.755;
blue and purple denote the two different alleles of the SNP. Circles and squares represent single events of transversion and transition at
CpG dinucleotide sites, respectively. Triangular sectors indicate expansion over time of clones carrying the resulting mutant protein
(selection). wt is used as an abbreviation for wild-type. The c.755C>G transversion (red circle) occurs rarely, but the resulting p.Ser252Trp
substitution (causing Apert syndrome in the germline) confers a strong selective advantage to the mutant SSC (red triangular sector),
leading to clonal expansion over time. The background mutation rate for the c.755C>T transition at this CpG dinucleotide (yellow
square) is higher (~3.3- to 10-fold),46,47 but the resulting mutant protein (p.Ser252Leu associated with Crouzon syndrome) confers
a weaker selective advantage compared to p.Ser252Trp, leading to slower clonal expansion (yellow triangular sectors). The original muta-
tion events occur randomly on either FGFR2 allele (blue or purple asterisk inmen heterozygous for the SNP) at different times within the
testis of an aging man.
(B) Accumulation of c.755C mutations in FGFR2 in sperm over time. Because of the rarity of the mutational events, the distribution of
the linked SNP (graphs, blue and purple columns on the right) is more skewed for the c.755C>G (above) than the c.755C>T mutation
(below); however, the prevalence of c.755C>G is greater than c.755C>T because of the greater selective advantage conferred by the
p.Ser252Trp compared to the p.Ser252Leu mutant protein.
(C) Mutational events taking place at FGFR3 position c.1138G cause achondroplasia. The c.1138G>A transition (green square) is more
frequent than the c.1138G>C transversion (light green circle) at this CpG dinucleotide site. Both resulting proteins encode p.Gly380Arg
that confers the same selective advantage to the mutant SSC (green triangular sectors). The difference in birth pre-
valence of achondroplasia caused by the two mutations is likely to be explained by the relative frequency of the original mutational
events at FGFR3 position c.1138. Although selection for the FGFR3 achondroplasia mutation is probably weaker than for the FGFR2
Apert mutation, nevertheless achondroplasia mutations occur more frequently because of the high intrinsic rate of the c.1138G>A
transition.rate of spontaneous transitions at CpG dinucleotides is up
to ~45 times higher than transversions at non-CpG
sites46,47,65 (Figure 1A), the relative contribution of this
effect (compared to selection) is likely to be small, although
not insignificant. This is illustrated by the c.1138G>A tran-
sition in FGFR3, which is ~35 times more commonly
reported in de novo cases of achondroplasia than the
c.1138G>C transversion;30,31 although both substitutions
encode the same p.Gly380Arg change in FGFR3 and are
therefore predicted to exhibit the same strength of positive
selection at the protein level, a difference in background
rates of mutability at this CpG dinucleotide is likely toThe Americaexplain the relative abundance of each substitution
observed in patients with achondroplasia (Figure 2C).
The relative contributions of intrinsic mutation rate and
selection also explain the differing abundance of themuta-
tions observed at FGFR2 position c.755C, again part of
a CpG dinucleotide (Figures 2A and 2B). Similar to the
achondroplasia situation, the endogenous rate of the
c.755C>T transition is predicted to be higher than that of
the c.755C>G transversion; however, at the protein level,
the resulting gain-of-function associated with the
c.755C>G, which encodes a stronger activating change
(p.Ser252Trp) in FGFR2—as exemplified by themore severen Journal of Human Genetics 90, 175–200, February 10, 2012 185
phenotypic characteristics of Apert syndrome—than the
c.755C>T (p.Ser252Leu) change associated with mild
Crouzon syndrome, is likely to result in a more significant
clonal expansion of the mutant SSC.56 By superimposing
these two components, both the higher absolute mutation
levels and the stronger allelic bias observed in sperm for the
c.755C>G compared to the c.755C>T substitution can be
explained (Figures 2A and 2B).
In summary, by combining the processes of background
variation in copy-errors with selfish selection in the
testis, the cardinal properties of PAE mutations (the
extreme male mutation bias, the paternal age effect and
the high germline mutation rate) are all accounted for.
Conceptually, the mechanisms involved in protein-driven
selfish selection of PAE mutations are not new but are
more familiar in the context of somatic mutations occur-
ring during neoplasia rather than in association with
germline disorders. These links are explored in the next
section.
Selfish Selection in the Testis: Spermatocytic
Seminoma and Other Links with Oncogenesis
In agreement with their highly localized mutational spec-
trum, biochemical evidence concurs that all known PAE
mutations result in activating proteins with gain-of-func-
tion properties (Table S1). Consistent with this, compar-
ison of the spectrum of PAE mutations observed in the
germline to that of somatic mutations found in malignan-
cies shows that the majority of them have been reported as
(or are allelic to) oncogenic mutations that, in different
cellular contexts, have been associated with various tumor
types (Table 1 and Figure 3), including endometrial cancer
(FGFR2); multiple myeloma and transitional cell carci-
noma of the bladder (FGFR3); hematological malignancies,
most often juvenile myelomonocytic leukemia (JMML)
(PTPN11/SHP2); and medullary thyroid carcinoma (RET).
Somatic HRAS mutations have been described in many
tumors, including cancers of the bladder, cervix, thyroid,
prostate, and breast; mutations at three hotspots encoding
(p.Gly12, p.Gly13, and p.Gln61) in the paralogous RAS
proteins (HRAS, KRAS, and NRAS) are found in ~30% of
all malignancies (Catalogue of Somatic Mutations In
Cancer [COSMIC] database).
The link between PAE genes implicated in selfish selec-
tion and their involvement in tumorigenesis led us to
propose that the clonal expansion associatedwith the selec-
tive advantage conferred to the mutant SSC by the FGFR2
Apert mutation could contribute to the formation of testic-
ular tumors.56,66 Although no somatic FGFR2 mutations
were identified in a panel of cancer cell lines and common
testicular tumors,66 we foundmutations in other PAE genes
in a distinct testicular neoplasm termed spermatocytic
seminoma (SPS).62 SPS is a rare germ cell tumor comprising
less than 5% of seminomas that is found exclusively in
the testis (with no ovarian equivalent), where it presents
as a slow growing well-circumscribed mass that rarely
metastasizes. Unlike classical seminomas that mostly affect186 The American Journal of Human Genetics 90, 175–200, Februaryyoung adults and originate during embryonic gonadal
development, SPSs derive from adult spermatogonia
and are found specifically in older men; the mean age at
diagnosis is around 54 years (age range: 19–92 years).67–69
Screening of 30 SPS identified two tumors with an
p.Lys650Glu alteration in FGFR3, identical to that causing
the lethal germline disorder TDII, whereas five further
samples carried a mutation within the Costello syndrome-
associated gene, HRAS.62 The HRAS alterations all oc-
curred at position p.Gln61 (three p.Gln61Arg and two
p.Gln61Lys), substitutions that confer stronger trans-
forming activity in vitro than the common p.Gly12Ser
Costello syndrome mutation.70 It is anticipated that germ-
line alterations at HRAS, which have never been reported,
will be analogous to the strongly activating p.Lys650Glu
in FGFR3 and might result in prenatal lethal pheno-
types.26,71
Another illustration of the link between selfish selection
in the testis and the principles of oncogenesis is provided
by FGFR3mutations altering p.Lys650, which were studied
in the sperm of 78 healthy donors following identifica-
tion of the c.1948A>G (p.Lys650Glu) mutations in SPS.
This study utilized RED/PCR coupled with massively
parallel sequencing62 to quantify each of the nine possible
substitutions occurring within the codon encoding
p.Lys650. Among these, six missense germline mutations
have been reported in association with four distinct clin-
ical phenotypes72,73 of variable severity, ranging from the
lethal condition TDII, to the much milder disorders hypo-
chondroplasia and acanthosis nigricans (MIM 100600). In
agreement with the proposal that oncogenic and selfish
properties depend on the biochemical strength conferred
by the encoded gain of function to the altered protein,
there was a strong correlation between the severity of the
associated clinical phenotype, the documented degree
of receptor activation,72 and the relative enrichment of
mutations in sperm observed for each of the mutations
encompassing codon p.Lys650 (Figure 1C).62 Moreover,
the relative abundance of each mutation in sperm
mirrored the distribution of somatic mutations altering
p.Lys650 reported in bladder cancers,62 further suggesting
that common molecular pathways and similar oncogenic
mechanisms operate in these two different cellular
contexts.
The selfish selection process also shares many similari-
ties with the formation of seborrheic keratoses (SK), benign
skin tumors that present as brown plaques with a verrucous
surface. The prevalence of these lesions increases with age
and are present in more than 80% of individuals over age
50; some people have many lesions of variable size (up to
a few centimeters). Analysis of multiple SK within individ-
uals reveals that these lesions frequently carry somatic
FGFR3 oncogenic mutations, which in the germline are
associated with TD.74 These similarities provide a useful
analogy whereby PAE mutations can be viewed as mono-
clonal expansion events promoting the formation of
‘‘mole-like’’ lesions within the testes of aging men. As10, 2012
Figure 3. Somatic and Germline Gain-
Of-Function Mutations Associated with
the Five PAE Genes
In each case, the name of the gene or
protein, its genomic location, and the
functional protein domains (see abbrevia-
tions below) are indicated; the most
common mutations (single-letter amino
acid codes) associated with cancer
(COSMIC database) are indicated above
the schematic of the protein along with
some of the cancers for which the muta-
tions have been described. The germline
mutations associated with congenital syn-
dromes (Human Gene Mutation Database
[HGMD] database) are indicated below
the protein and are color coded according
to the associated disorders (key on the
figure). A few complex rearrangements
and splice-site mutations are omitted for
clarity. Proteins are numbered and drawn
to scale (except for HRAS, for which the
scale is 3:1, and RET, for which the scale
is 0.9:1) according to the reference se-
quences (for RefSeq, see footnote b in
Table 1); the length in amino acids (AA)
is indicated in bold. The following abbrevi-
ations are used: Ig, immunoglobulin-like
domain; TM, transmembrane domain;
TK, tyrosine kinase domain; P loop, phos-
phate-binding loop; Switch, switch do-
main; CVLS, prenylation signal sequence;
SH2, Src Homology 2 domain; PTP, phos-
photyrosine domain; CAD, cadherin
domain; CRD, cysteine-rich domain; SAD-
DAN, severe achondroplasia with develop-
mental delay and acanthosis nigricans;
AN, acanthosis nigricans; and JMML, juve-
nile myelomonocytic leukemia.with SKs, for most PAE mutations, the clonal expansion of
mutant SSC appears to be subexponential,56 suggesting
that it is limited by growth arrest or activation of a cellular
senescence response that restrains tumor progression.75,76
Taken together this evidence bolsters the view that PAE
mutations should essentially be considered as somaticThe American Journal of Human Genmutations with oncogenic properties
and that selfish selection in the
testis operates by the same general
principles that have been described
in tumorigenesis. However, these
oncogenic mutations are unique
because they are taking place within
germ cells rather than somatic
cells. Because mutant SSCs are able
to produce sperm that can transmit
the genetic lesion (as a germline
mutation) to the offspring, the conse-
quences of this process extend to
the next generation. As a result, a
single mutational event results both
in a somatic phenotype that causeslocalized cellular growth—and in extreme cases leads
to the formation of a testicular tumor—as well as a
germline phenotype associated with a specific syndrome,
uniquely unifying the concepts of germline and somatic
mutation to an event taking place within a single cell,
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Table 4. Multiple Nucleotide Substitutions Identified in PAE Disorders
Germline Substitutiona Protein Changea Associated Disorder
Number of Cases
Reported References
FGFR2
c.514_515delGCinsTT p.Ala172Phe Pfeiffer syndrome 1 Kan et al.32, Ibrahimi et al.180
c.755_756delCGinsTT p.Ser252Phe Apert syndrome 2 Lajeunie et al.181,
Oldridge et al.182
c.755_756delCGinsTC p.Ser252Phe Apert syndrome 1b Goriely et al.57
c.755_756delCGinsTC p.Ser252Phe Apert syndrome sperm Goriely et al.56
c.755_756delCGinsAC p.Ser252Tyr not known sperm Goriely et al.57
c.755_757delCGCinsTCT p.Ser252_Pro253
delinsPheArg
Pfeiffer syndrome 1 Oldridge et al.182
c.[755C>T; 943G>T] p.[Ser252Leu; Ala315Ser] syndactyly 1 Goriely et al.57, Wilkie et al.183,
Ibrahimi et al.184
c.1024_1025delGCinsCT p.Cys342Ser Pfeiffer syndrome 1 Cornejo-Roldan et al.185
FGFR3
c.[1130T>G; 1138G>A] p.[Leu377Arg; Gly380Arg] severe form of
achondroplasia
1 Rump et al.186
c.1138_1139delGGinsAA p.Gly380Lys hypochondroplasia 1 Santos et al.187
c.[1454A>G; 1620C>A] p.[Gln485Arg; Asn540Lys] thanatophoric dysplasia 1 Pannier et al.188
HRAS
c.35_36delGCinsAA p.Gly12Glu Costello syndrome 1 Kerr et al.189
c.35_36delGCinsTT p.Gly12Val Costello with
cardiomyopathy
2 Aoki et al.71,
van der Burgt et al.190
RET
c.[1895_1897delGCinsCG;
1900T>C]
p.[Glu632_Cys634
delinsAspValArg]
Men2A 1 Mulligan et al.191
c.1902_1903delCCinsGG p.[Cys634_Arg635
delinsTrpGly]
Men2A 1 Lips et al.192
c.[2332G>A; 2411G>A] p.[Val778Ile; Val804Met] FMTC 1 Kasprzak et al.193
c.[2411G>A; 2417A>G] p.[Val804Met; Tyr806Cys] Men2B 1b Miyauchi et al.79,
Iwashita et al.80
c.[2411G>A; 2531G>T] p.[Val804Met; Arg844Leu] FMTC 1 Bartsch et al.194
c.[2411G>A; 2714A>G] p.[Val804Met; Ser904Cys] Men2B 1 Menko et al.195
c.2647_2648delGCinsTT p.Ala883Phe Men2B 5 Gimm et al.196,
Smith et al.197, Jasim et al.198
FMTC is used as an abbreviation for familial medullary thyroid carcinoma.
a The RefSeq used for numbering are given in footnotes a and b of Table 1.
b Cases where the second ‘‘hit’’ is documented to have been acquired de novo on the paternal allele.Multiple Nucleotide Substitutions Are a Frequent
Feature of Selfish Selection
By analogy with tumorigenesis, where accumulation of
sequential independent mutations is an important process
contributing to oncogenesis and tumor progression,77,78
there is an enrichment of PAE mutations caused by
multiple nucleotide substitutions (Table 4). Many of these
mutations encode amino acid substitutions conferring
strong and/or unique gain-of-function properties that,
owing to the specific features of the genetic code, could
not arise as single-nucleotide substitutions, whereas others188 The American Journal of Human Genetics 90, 175–200, Februaryare caused by mutations located in different codons that
synergize with one another and potentiate the activity of
the mutant protein. On the basis of the estimated back-
ground rate of double mutations (~1011),46 if these multi-
ple substitutions had only arisen by chance, we would
anticipate finding less than one case of any double substi-
tution in the entire human population. Consistent with
progressive enrichment for selectively advantageous
mutations, we showed in the case of an Apert syndrome
patient with a rare p.Ser252Phe missense change in FGFR2
(c.755_756delCGinsTC), that this double substitution10, 2012
Figure 4. PAE Disorders Cluster within the Receptor Tyrosine Kinase (RTK)-RAS Signaling Pathway
The known PAE disorders (boxes) and the five PAE proteins that fulfill all three criteria to belong to the PAE class (as defined in the text)
are indicated in blue. Other candidate PAE disorders (Table 2) are in black within the boxes. Signaling downstream of RAS involves the
RAF/MEK/ERK (MAPK-ERK branch) (in red) and the PI3K-AKT-mTOR (in green) pathways. TheMEK1/2 inhibitor (in red box) specifically
blocks the phosphorylation of ERK1/2. For details and abbreviations see the main text.had arisen sequentially over two generations.57 A similar
process has been reported for double substitutions in RET
causing Men2B.79,80
Dysregulation of Growth Factor Receptor-RAS
Signaling Links All PAE Disorders
The quantitative data supporting selfish spermatogonial
selection have emerged from studies of FGFR2 and FGFR3
mutations, but the same principles are likely to extend to
the other PAE disorders. By considering Men2A/B and
Noonan and Costello syndromes, we can gather further
clues about the likely biological and molecular mecha-
nisms underlying selfish selection. Indeed, of the associ-
ated mutated genes, RET encodes a well-characterized
regulator of SSC proliferative behavior (see next section),
whereas PTPN11/SHP2 and HRAS encode key signaling
transduction components located downstream of FGFR2,
FGFR3, and RET, positioning all five PAE genes within
a single molecular pathway, the growth factor receptor-
RAS pathway.
As summarized in Figure 4, the RAS signaling cascade is
activated upon binding of specific ligands to their cognate
cell surface growth factor receptor tyrosine kinases (FGFRs
and RET). This signaling cascade controls many different
cellular functions, including proliferation, differentiation,
survival, and apoptosis. The three RAS genes (HRAS,
KRAS, and NRAS) encode small GTPases that act as key
signal regulators, a role mediated by their ability to cycle
between an active guanosine triphosphate (GTP)-boundThe Americaand an inactive guanosine diphosphate (GDP)-bound
conformation. In their active state, RAS proteins transduce
signals through different effectors, such as the mitogen-
activated protein kinases (MAPK) or phosphoinositide
3-kinase (PI3K). The MAPK pathway is activated by recruit-
ment of the RAF serine threonine kinases (ARAF, BRAF, and
CRAF) to the plasmamembrane where they phosphorylate
the MEK1 (MAP2K1) and MEK2 (MAP2K2) kinases, which
in turn phosphorylate the extracellular signal-regulated
kinases (ERK) ERK1 (MAPK3) and ERK2 (MAPK1). Upon
phosphorylation, ERKs translocate to the nucleus where
they modulate the activity of various transcription factors.
Alternatively, activated GTP-bound RAS also interacts with
the catalytic subunits of PI3K, which lead to production of
phosphatidylinositol 3,4,5,-triphosphate (PIP3) at the
plasma membrane. This signal is then transduced through
PIP3 targets by phosphorylation of AKT (also known as
protein kinase B [PKB]) serine/threonine kinases (pAKT)
or stimulation of mammalian target of rapamycin
(mTOR). In addition, the PI3K-AKT pathway can bypass
RAS and be directly activated in response to growth factor
stimulation.
Two lines of evidence suggest that dysregulation of the
growth factor receptor-RAS pathway leading to selfish
selection of PAE mutations is mediated by downstream
activation of the MAPK-ERK branch. As well as the estab-
lished PAE genes PTPN11/SHP2 (an upstream regulator of
RAS) and HRAS itself, paternal age effects (but in the
absence of formal demonstration of the parental originn Journal of Human Genetics 90, 175–200, February 10, 2012 189
of the causative de novo mutations) have also been
described for cardio-facio-cutaneous (CFC) syndrome
(Table 2) caused by mutations in downstream components
of the RAS-(MAPK) pathway (BRAF, MEK1, and MEK2),
directly implicating MAPK-ERK in the pathophysiology
of these disorders. More indirectly, the phenotypic rescue
of mouse models for Apert81 and Noonan82,83 syndromes,
through treatment with specific pathway inhibitors
(MEK1/MEK2 inhibitor) (Figure 4) or by genetic means84
provides strong evidence that these particular phenotypes,
which include craniosynostosis, growth delay, facial dys-
morphia, cardiac defects, and/or pulmonary valve stenosis,
are caused by abnormal signal transduction through the
MAPK-ERK branch.
Notwithstanding these observations, there is also indi-
rect evidence implicating the PI3K-AKT cascade in selfish
selection. For example, fibroblasts from Costello syndrome
patients show an increased level of phosphorylated AKT
compared with the level in controls, whereas MEK/ERK
phosphorylation remains unchanged.85 Functional data
(discussed in the next section) also support a key role for
the PI3K/AKT pathway in SSC self-renewal.
PAE Genes Regulate Spermatogonial Self-Renewal
Although orthologs of all five PAE genes are expressed
during mammalian spermatogenesis,57,62,69,86–89 the func-
tional role of RET has been most extensively characterized
inmice. Although Ret is expressed on the surface of SSCs,90
its ligand Glial-derived neurotrophic factor (Gdnf) is ex-
pressed by the supporting Sertoli cells, from where it regu-
lates dose-dependent self-renewal and differentiation of
SSCs. Heterozygous knock-out of Gdnf is characterized by
a progressive loss of undifferentiated spermatogonia that
results in infertility and Sertoli cell-only seminiferous
tubules in older animals,91 whereas Gdnf overexpression
in SSC produces clusters of spermatogonia that are unable
to differentiate and eventually develop into seminomatous
tumors.92
The crucial role of Gdnf in controlling the balance
between SSC proliferation and differentiation during sper-
matogenesis is also illustrated by in vitro analysis. Long-
term culture of murine SSC can only be supported in
minimal serum-free media conditions in the presence of
GDNF and FGF-2 (fibroblast growth factor-2); addition
of FGF-2 to the culture medium is essential and acts syner-
gistically with GDNF to promote in vitro expansion of
SSCs.93 Under these conditions, isolated SSCs proliferate
over long periods (>2 years) and can be used in functional
transplantation assays in which the derived cells produce
germ cell colonies, reconstituting the entire spermato-
genic process in recipient testes from infertile mice.93,94
Multiple signaling pathways are activated in response to
GDNF/FGF-2 stimulation; murine SSCs cultured with
small molecule inhibitors of Akt showed significant
impairment of SSC maintenance following transplanta-
tion,95 suggesting a critical role for the PI3K-AKT pathway
in promoting SSC survival and/or proliferation. However,190 The American Journal of Human Genetics 90, 175–200, FebruaryAKT activation alone was not sufficient to drive SSC self-
renewal, which could only be achieved upon costimula-
tion with FGF-2.96 Notably, Lee et al.97 showed that the
minimal culture requirements for GDNF/FGF-2 could be
bypassed by transfecting SSCs with an activated form of
Hras (HrasGly12Val). Hras activation promoted long-term
self-renewal of SSCs that underwent spermatogenesis
after transplantation and, as in the case of Gdnf overex-
pression, HrasGly12Val-transfected SSCs produced semi-
nomatous tumors in the mouse testis. The use of specific
pathway inhibitors showed that this effect was mainly
mediated through the PI3K-AKT signal transduction
pathway, although an intact MAPK-ERK cascade also facil-
itated proliferation.97
The detailed molecular machinery and cellular mecha-
nisms involved in controlling SSC self-renewal and
differentiation during spermatogenesis are still poorly
understood: the extent to which homeostasis is main-
tained through control of self-renewal, proliferation,
differentiation, and/or survival of cells in the SSC lineage
remains unclear.98,99 Moreover, the data reviewed above
have been generated with rodent SSCs, which share some
but not all of their features with their human counterparts.
Although research on human SSCs has been limited,
culture of spermatogonia derived from testes of freshly
deceased donors showed that upregulation of the MAPK-
ERK pathway was involved in their proliferation.100
In summary, these in vitro and in vivo data concur that
the activity of the growth factor receptor-RAS signaling
pathway is integral to the regulation of SSCs and relies
on a complex crosstalk among multiple effectors, in-
cluding the PI3K-AKT and MAPK-ERK transduction
cascades. Strikingly, all known PAE disorders are caused
by mutations in genes involved in this process, supporting
the idea that the paternal age effect is mediated through
dysregulation of RAS signaling and alteration of the
growth and proliferative properties of SSCs.
Does Selfish Selection Contribute to the Origins
of Complex Diseases?
Thus far, we have focused on established PAE disorders and
have highlighted how advanced paternal age and selfish
selection can be explained in relation to the biological
and molecular mechanisms controlling population
dynamics of SSCs. To what extent is this interpretation
relevant to paternal age effects associated with more
common disorders that have a complex etiology?
It is apparent that spermatogonial populations are
subject to regular turnover, and therefore, any mutation
that happens to arise in, or near, any gene controlling
the cellular and homeostatic properties of SSC is a potential
target for selection and enrichment in SSCs. Clearly, many
components of the growth factor receptor-RAS signaling
pathway are predicted to be vulnerable to this process,
but in theory, any pathway that has been implicated in
either oncogenesis (COSMIC database) or cell competi-
tion101 and is expressed in the testis89,102,103 could also10, 2012
Figure 5. Long-Term Consequences of Selfish Selection in the Testis
Blue ovals represent the testis at three ages from puberty (left) to senescence (right). During the recurrent rounds of replication required
for spermatogenesis and SSC self-renewal, stochastic mutations (represented by X) occur randomly in the testis. Depending on the func-
tional consequence of the resulting mutation for the SSC, three scenarios are illustrated. Functionally neutral mutations (in yellow; left
part of each testis) do not accumulate and are associated with a very low risk of individual transmission (~108, the background rate of
nucleotide substitution in the genome). In red (right part of the testis) are typical PAEmutations that confer a strong selective advantage
to the mutant SSC, leading over time to the formation of large ‘‘mole-like’’ clones (ovals) and an increased risk of transmission in older
men (up to 1,000-fold higher than the backgroundmutation rate). In rare cases, these mutations are associated with spermatocytic semi-
noma (SPS). In orange (bottom part of the testis) is depicted an intermediate scenario for mutations withmilder selective advantage (i.e.,
weak gain-of-function, change in copy number or regulation of expression) that are enriched over time in SSC to a lesser extent (>1- to
100-fold). Many such mutational targets could potentially exist. Although strongly activating mutations associated with classical PAE
disorders are deleterious and will be rapidly eliminated because of low reproductive fitness, neutral and mildly pathogenic mutations
are potentially transmissible over many generations, contributing to genetic heterogeneity. Some mildly pathogenic mutations,
although associated with deleterious phenotypes, might be maintained in the population either by recurrent mutation or because
they provide a beneficial fitness trait during spermatogenesis.be a target. Based on this interpretation, the spectrum
of mutations subject to selfish selection is unlikely to be
limited to a handful of strongly activating missense sub-
stitutions in known oncogenes. Selection could also
involve loss-of-function mechanisms (that might result
in haploinsufficiency104), changes in regulatory regions
(resulting in altered gene expression105–107), differences
in gene dosage (leading to cell competition108), or copy-
number variations (CNV) in genes controlling SSC prolifer-
ative behavior.
The case of CNVs is of particular interest because
genomic deletions and duplications are known to affect a
wide range of human phenotypes including many
Mendelian traits and complex disorders such as autism
and schizophrenia.109 Recurrent CNVs mediated by un-
equal crossing-over between large near-identical segmental
duplications are recombination-dependent (meiotic)
events.110–112 In contrast, rare CNVs generated by nonre-
current rearrangements mostly originate through replica-
tion-based processes, involving different molecular mech-
anisms (e.g., fork stalling and template switching [FoSTeS]The Americaand/or microhomology-mediated break-induced replica-
tion [MMBIR]).113–115 Because of this mitotic origin, it is
anticipated that nonrecurrent CNVs should preferentially
arise in male germ cells. Investigations into the parental
origin of de novo nonrecurrent CNVs are under way116
but are laborious and require a careful separation of spon-
taneous genomic rearrangements into likely recombina-
tion- and replication-based events.117,118
To appreciate the long-term consequences for genome
evolution, it is important to consider the interplay between
the strength of selfish selection occurring in the testis and
the impact of these mutations on the fitness of the
offspring. Given the severe phenotypes they cause, the
pathogenic alleles associated with classical PAE disorders
areunlikely to segregate formanygenerations and therefore
are predicted to have little impact on overall disease burden
(Figure 5, red mutations). However, selfish mutations asso-
ciated with weaker selective advantage in the testis (and
leading to lower levels of enrichment in sperm) that are
anticipated to cause milder or incompletely penetrant
phenotypes are a potential source of heritable geneticn Journal of Human Genetics 90, 175–200, February 10, 2012 191
variation that might contribute both to adaptive evolution
and to the genetic burden of disease (Figure 5, orangemuta-
tions). Given that bothMAPK-ERK and PI3K-AKT signaling
play important roles in brain development, learning,
memory, synaptic plasticity, and cognition,119,120 subtle
alterations of these pathways are likely to contribute to
the pathology of learning disability and neurocognitive
disorders, as well as cancer. In this context it is relevant
that several epidemiological studies have reported an asso-
ciation between advanced paternal age and predisposition
to neurocognitive disorders such as schizophrenia9,121,122
and autism.8,123,124 Although there are several confound-
ing factors that could explain these observations,13 selfish
selection provides one plausible mechanism. Notably,
recent reports have highlighted the importance of rare
(or private) de novo mutations (both point mutations
and CNVs) in the causation of common disorders such
as learning disabilities,125 autism,126–128 and schizo-
phrenia.129–132 Information on parental origin and
paternal age is not available in most of these studies; it
will be important to collect these data systematically.
The emerging picture in neurocognitive disorders
suggests that the genetic component of disease risk arises
both from de novo mutations and from segregating
variants that are individually mildly deleterious and/or
show clinical variability in expressivity. In most cases,
the disease manifests through an adverse combination of
mild-risk alleles (in familial cases) and/or when de novo
mutations are acquired in a general sensitized background
that is already loaded with low-penetrant pathogenic
variants (in simplex cases).133 Notably, comprehensive
unbiased screens for pathogenic CNVs associated with
autism have highlighted the importance of genomic
regions containing functional gene sets involved in cell
proliferation and in GTPase/RAS signaling.126,134 Similarly,
FGFR135 and the AKT-mTOR136–138 signaling pathways
have been implicated in the pathology of schizophrenia.
In other words, the pathways implicated in the pathogen-
esis of these neurocognitive disorders overlap substantially
with those subject to selfish selection in the testis and are
therefore potential targets for this process (Figure 5, orange
mutations).139
Spermatogenesis, Weakly Pathogenic Variants,
and Evolution
Aside from selfish selection promoting clonal expansion
of mutant SSCs in the context in which mutant cells
are surrounded by wild-type counterparts (i.e., mosaic—
involving the interaction between two genetically distinct
cell populations), mutations in components of spermato-
gonial signaling pathways might also be advantageous
in a constitutive state (i.e., when all the cells are genotyp-
ically identical). So long as they are not overly deleterious
to the organism, low-penetrance pathogenic alleles
could segregate over many generations and be main-
tained, or even become fixed in the population, through
a mechanism of balancing selection (i.e., as a trade-off192 The American Journal of Human Genetics 90, 175–200, Februarybetween a beneficial fitness trait during spermatogenesis
that compensates for the deleterious effect in other
cellular contexts) (Figure 5). Several lines of evidence
are consistent with this interpretation: (1) comparative
evolutionary studies suggest that a large proportion of
genes expressed in spermatogenesis (including genes
that promote germ cell development, apoptosis and
tumor suppression) are under positive selection;102 (2)
the intriguing case of a patient diagnosed with both Kline-
felter syndrome (a condition normally associated with
male infertility and azoospermia) and achondroplasia
who fathered a child suggests that the presence of the acti-
vating FGFR3 mutation might have rescued the testicular
functioninthis individual;140 (3) severalgenome-wideasso-
ciation studies have identified common variants close to
PAE genes associated with increased disease risk, including
SNPs in or near FGFR2 andMAP3K1 in breast cancer,141,142
FGFR1 andFGFR2 in schizophrenia,143,144 FGFR3 inbladder
cancer,145 HRAS in several cancer types,146–148 and RET
in Hirschsprung disease105 or genomic regions associated
with schizophrenia149 and other complex diseases150
showing signatures of positive selection.
Perspectives and Conclusions
Driven by recognition of epidemiological paternal age
effects, targeted molecular approaches in a handful of
monogenic disorders have led to a clearer understanding
of the molecular mechanisms and principles underlying
this phenomenon. Owing to the technical challenges,
only a few base pairs in the human genome have been
systematically interrogated to date. Nevertheless, the data
suggest that the spermof allmen are progressively enriched
for PAE mutations as they age and highlight that selfish
selection is likely to be a universal process. A major chal-
lenge will be to establish how many sites in our genome
are subject to selfish selection with the eventual aim of ob-
taining a frequency spectrum of point mutation (as well as
CNV-based mutational processes) at every genomic posi-
tion. This will establish whether the few documented PAE
disorders are indeed extreme examples of a much more
common process. So far, whole-genome sequences of a
few family trios48,50 have shown that the transgenerational
mutation load and parental origin for each de novo muta-
tion52 can be directly determined. As much larger such
data sets become available, it should be possible to establish
the relative contribution of selfish selection to genetic
heterogeneity and to disease risk by ascertaining whether
paternally-derivedmutations are truly randomor, as selfish
selectionpredicts,whether there is a significant enrichment
of functional alleles in or near genes involved in the control
of spermatogonial self-renewal. Given that selfish selection
might also be responsible for the emergence of advanta-
geous traits involving cognition, increased brain size, or
adaptation to new environments, thesemechanismsmight
have contributed to human evolution.103,151
Current data already provide valuable new evidence for
genetic counseling of couples having children affected10, 2012
with spontaneous PAE disorders. Although high-level
somatic and/or germline mosaicism has very occasionally
been observed,152,153 such cases are swamped out by the
much more prevalent selfish selection mechanism.
Provided that genetic testing on parents’ blood shows no
evidence of mosaic mutation, the recurrence risk for
further affected children is likely to be extremely low
(below 1 in 1,000, for all paternal ages). This information
could influence parental decisions on whether to opt for
invasive prenatal testing in future pregnancies. The local-
ized nature of PAE mutations, and their paternal origin,
make these disorders very good candidates for prenatal
screening via free fetal DNA from maternal plasma;
because average paternal age at conception has been
steadily increasing,15 it could become cost-effective to
devise a systematic screen targeting common PAE muta-
tions in the case of older fathers.154–156
New technologies, such as the so-called third generation
of single-molecule sequencing157 that does not rely on
PCR amplification prior to sequencing, are anticipated to
allow further elucidation of the impact of the selfish
selection mechanism. Whole-genome sequencing of
single-cells might soon be used to directly quantify the
mutational load carried by individual sperm cells.158,159
Whether applied to single sperm cells, fetal cells in
maternal plasma, or oncogenic mutations in the circula-
tion,160 we are bound to learnmore about the contribution
of selfish selection to human health and evolution. Unusu-
ally, humans represent in many ways the ideal ‘‘model’’
organism to study these ultrarare mutational processes.Supplemental Data
Supplemental Data include one table and Supplemental Refer-
ences and can be found with this article online at http://www.
cell.com/AJHG/.Acknowledgments
This review is dedicated to the memory of James F. Crow (1916–
2012), a pioneer in the study of paternal age effects. We thank
Gil McVean (Oxford, UK) and Ewa Rajpert-DeMeyts (Copenhagen,
Denmark) for their long-term collaboration in this work, members
of the Wilkie lab for critical reading of the manuscript and the
Wellcome Trust (091182) for financial support.Web Resources
The URLs for data presented herein are as follows:
COSMIC, http://www.sanger.ac.uk/genetics/CGP/cosmic/
England andWales Birth Census data series FM1, http://www.ons.
gov.uk/ons/statbase
HGMD, http://www.hgmd.cf.ac.uk/ac/index.php
National Center for Biotechnology Information Reference
Sequence (RefSeq) database, http://www.ncbi.nlm.nih.gov/
RefSeq/
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org/The AmericaReferences
1. Hassold, T., and Hunt, P. (2009). Maternal age and chromo-
somally abnormal pregnancies:What we know andwhat we
wish we knew. Curr. Opin. Pediatr. 21, 703–708.
2. Risch, N., Reich, E.W., Wishnick, M.M., and McCarthy, J.G.
(1987). Spontaneous mutation and parental age in humans.
Am. J. Hum. Genet. 41, 218–248.
3. Green, R.F., Devine, O., Crider, K.S., Olney, R.S., Archer, N.,
Olshan, A.F., and Shapira, S.K.; National Birth Defects
Prevention Study. (2010). Association of paternal age and
risk for major congenital anomalies from the National Birth
Defects Prevention Study, 1997 to 2004. Ann. Epidemiol.
20, 241–249.
4. Yip, B.H., Pawitan, Y., and Czene, K. (2006). Parental
age and risk of childhood cancers: A population-based
cohort study from Sweden. Int. J. Epidemiol. 35, 1495–
1503.
5. Murray, L., McCarron, P., Bailie, K., Middleton, R., Davey
Smith, G., Dempsey, S., McCarthy, A., and Gavin, A.
(2002). Association of early life factors and acute lympho-
blastic leukaemia in childhood: Historical cohort study.
Br. J. Cancer 86, 356–361.
6. Choi, J.Y., Lee, K.M., Park, S.K., Noh, D.Y., Ahn, S.H., Yoo,
K.Y., and Kang, D. (2005). Association of paternal age at
birth and the risk of breast cancer in offspring: A case
control study. BMC Cancer 5, 143.
7. De Meyer, T., Rietzschel, E.R., De Buyzere, M.L., De Bacquer,
D., Van Criekinge, W., De Backer, G.G., Gillebert, T.C., Van
Oostveldt, P., and Bekaert, S.; Asklepios investigators.
(2007). Paternal age at birth is an important determinant
of offspring telomere length. Hum. Mol. Genet. 16, 3097–
3102.
8. Grether, J.K., Anderson, M.C., Croen, L.A., Smith, D., and
Windham, G.C. (2009). Risk of autism and increasing
maternal and paternal age in a large north American popu-
lation. Am. J. Epidemiol. 170, 1118–1126.
9. Malaspina, D. (2001). Paternal factors and schizophrenia
risk: De novo mutations and imprinting. Schizophr. Bull.
27, 379–393.
10. Frans, E.M., Sandin, S., Reichenberg, A., Lichtenstein, P.,
La˚ngstro¨m, N., and Hultman, C.M. (2008). Advancing
paternal age and bipolar disorder. Arch. Gen. Psychiatry 65,
1034–1040.
11. Saha, S., Barnett, A.G., Foldi, C., Burne, T.H., Eyles, D.W.,
Buka, S.L., and McGrath, J.J. (2009). Advanced paternal age
is associated with impaired neurocognitive outcomes during
infancy and childhood. PLoS Med. 6, e40.
12. Chen, X.K., Wen, S.W., Krewski, D., Fleming, N., Yang, Q.,
and Walker, M.C. (2008). Paternal age and adverse birth
outcomes: Teenager or 40þ, who is at risk? Hum. Reprod.
23, 1290–1296.
13. Petersen, L., Mortensen, P.B., and Pedersen, C.B. (2011).
Paternal age at birth of first child and risk of schizophrenia.
Am. J. Psychiatry 168, 82–88.
14. Toriello, H.V., and Meck, J.M.; Professional Practice and
Guidelines Committee. (2008). Statement on guidance for
genetic counseling in advanced paternal age. Genet. Med.
10, 457–460.
15. Bray, I., Gunnell, D., and Davey Smith, G. (2006). Advanced
paternal age: How old is too old? J. Epidemiol. Community
Health 60, 851–853.n Journal of Human Genetics 90, 175–200, February 10, 2012 193
16. Orioli, I.M., Castilla, E.E., and Barbosa-Neto, J.G. (1986). The
birth prevalence rates for the skeletal dysplasias. J. Med.
Genet. 23, 328–332.
17. Waller, D.K., Correa, A., Vo, T.M., Wang, Y., Hobbs, C., Lan-
glois, P.H., Pearson, K., Romitti, P.A., Shaw, G.M., and Hecht,
J.T. (2008). The population-based prevalence of achondro-
plasia and thanatophoric dysplasia in selected regions of
the US. Am. J. Med. Genet. A. 146A, 2385–2389.
18. Cohen, M.M., Jr., Kreiborg, S., Lammer, E.J., Cordero, J.F.,
Mastroiacovo, P., Erickson, J.D., Roeper, P., and Martı´nez-
Frı´as, M.L. (1992). Birth prevalence study of the Apert
syndrome. Am. J. Med. Genet. 42, 655–659.
19. Tolarova, M.M., Harris, J.A., Ordway, D.E., and Vargervik, K.
(1997). Birth prevalence, mutation rate, sex ratio, parents’
age, and ethnicity in Apert syndrome. Am. J. Med. Genet.
72, 394–398.
20. Orioli, I.M., Castilla, E.E., Scarano, G., and Mastroiacovo, P.
(1995). Effect of paternal age in achondroplasia, thanato-
phoric dysplasia, and osteogenesis imperfecta. Am. J. Med.
Genet. 59, 209–217.
21. Rannan-Eliya, S.V., Taylor, I.B., DeHeer, I.M., VanDenOuwe-
land, A.M., Wall, S.A., and Wilkie, A.O.M. (2004). Paternal
origin of FGFR3mutations in Muenke-type craniosynostosis.
Hum. Genet. 115, 200–207.
22. Schuffenecker, I., Ginet, N., Goldgar, D., Eng, C., Chambe, B.,
Boneu, A., Houdent, C., Pallo, D., Schlumberger, M., Thivo-
let, C., and Lenoir, G.M. (1997). Prevalence and parental
origin of de novo RET mutations in multiple endocrine
neoplasia type 2A and familial medullary thyroid carcinoma.
Le Groupe d’Etude des Tumeurs a Calcitonine. Am. J. Hum.
Genet. 60, 233–237.
23. Carlson, K.M., Bracamontes, J., Jackson, C.E., Clark, R., La-
croix, A., Wells, S.A., Jr., and Goodfellow, P.J. (1994).
Parent-of-origin effects in multiple endocrine neoplasia
type 2B. Am. J. Hum. Genet. 55, 1076–1082.
24. Tartaglia, M., Cordeddu, V., Chang, H., Shaw, A., Kalidas, K.,
Crosby, A., Patton, M.A., Sorcini, M., van der Burgt, I., Jeffery,
S., and Gelb, B.D. (2004). Paternal germline origin and sex-
ratio distortion in transmission of PTPN11 mutations in
Noonan syndrome. Am. J. Hum. Genet. 75, 492–497.
25. Sol-Church,K., Stabley,D.L.,Nicholson,L.,Gonzalez, I.L., and
Gripp, K.W. (2006). Paternal bias in parental origin of HRAS
mutations in Costello syndrome. Hum. Mutat. 27, 736–741.
26. Zampino, G., Pantaleoni, F., Carta, C., Cobellis, G., Vasta, I.,
Neri, C., Pogna, E.A., De Feo, E., Delogu, A., Sarkozy, A., et al.
(2007). Diversity, parental germline origin, and phenotypic
spectrum of de novo HRAS missense changes in Costello
syndrome. Hum. Mutat. 28, 265–272.
27. Schulz, A.L., Albrecht, B., Arici, C., van der Burgt, I., Buske,
A., Gillessen-Kaesbach, G., Heller, R., Horn, D., Hu¨bner,
C.A., Korenke, G.C., et al. (2008). Mutation and phenotypic
spectrum in patients with cardio-facio-cutaneous and Cost-
ello syndrome. Clin. Genet. 73, 62–70.
28. Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hin-
dorff, L.A., Hunter, D.J., McCarthy, M.I., Ramos, E.M., Car-
don, L.R., Chakravarti, A., et al. (2009). Finding the missing
heritability of complex diseases. Nature 461, 747–753.
29. Wilkie, A.O.M., Slaney, S.F., Oldridge, M., Poole, M.D., Ash-
worth, G.J., Hockley, A.D., Hayward, R.D., David, D.J., Pul-
leyn, L.J., Rutland, P., et al. (1995). Apert syndrome results
from localized mutations of FGFR2 and is allelic with Crou-
zon syndrome. Nat. Genet. 9, 165–172.194 The American Journal of Human Genetics 90, 175–200, February30. Rousseau, F., Bonaventure, J., Legeai-Mallet, L., Pelet, A.,
Rozet, J.M., Maroteaux, P., Le Merrer, M., and Munnich, A.
(1994). Mutations in the gene encoding fibroblast growth
factor receptor-3 in achondroplasia. Nature 371, 252–254.
31. Bellus, G.A., Hefferon, T.W., Ortiz de Luna, R.I., Hecht, J.T.,
Horton,W.A.,Machado,M., Kaitila, I.,McIntosh, I., and Fran-
comano, C.A. (1995). Achondroplasia is defined by recurrent
G380Rmutations of FGFR3. Am. J. Hum.Genet. 56, 368–373.
32. Kan, S.H., Elanko, N., Johnson, D., Cornejo-Roldan, L., Cook,
J., Reich, E.W., Tomkins, S., Verloes, A., Twigg, S.R.F., Rannan-
Eliya, S., et al. (2002). Genomic screening of fibroblast
growth-factor receptor 2 reveals a wide spectrum of muta-
tions in patients with syndromic craniosynostosis. Am. J.
Hum. Genet. 70, 472–486.
33. Vajo, Z., Francomano, C.A., and Wilkin, D.J. (2000). The
molecular and genetic basis of fibroblast growth factor
receptor 3 disorders: The achondroplasia family of skeletal
dysplasias, Muenke craniosynostosis, and Crouzon
syndrome with acanthosis nigricans. Endocr. Rev. 21, 23–39.
34. Aoki, Y., Niihori, T., Narumi, Y., Kure, S., and Matsubara, Y.
(2008). The RAS/MAPK syndromes: Novel roles of the RAS
pathway in human genetic disorders. Hum. Mutat. 29,
992–1006.
35. Kratz, C.P., Zampino, G., Kriek, M., Kant, S.G., Leoni, C., Pan-
taleoni, F., Oudesluys-Murphy, A.M., Di Rocco, C., Kloska,
S.P., Tartaglia, M., and Zenker, M. (2009). Craniosynostosis
in patients with Noonan syndrome caused by germline
KRAS mutations. Am. J. Med. Genet. A. 149A, 1036–1040.
36. Tartaglia, M., Zampino, G., and Gelb, B.D. (2010). Noonan
syndrome: Clinical aspects and molecular pathogenesis.
Mol Syndromol 1, 2–26.
37. Raue, F., and Frank-Raue, K. (2010). Update multiple endo-
crine neoplasia type 2. Fam. Cancer 9, 449–457.
38. Vogel, F., and Rathenberg, R. (1975). Spontaneous mutation
in man. Adv. Hum. Genet. 5, 223–318.
39. Crow, J.F. (2000). The origins, patterns and implications of
human spontaneous mutation. Nat. Rev. Genet. 1, 40–47.
40. Penrose, L.S. (1955). Parental age and mutation. Lancet 269,
312–313.
41. Makova, K.D., and Li, W.H. (2002). Strong male-driven
evolution of DNA sequences in humans and apes. Nature
416, 624–626.
42. Taylor, J., Tyekucheva, S., Zody, M., Chiaromonte, F., and
Makova, K.D. (2006). Strong and weak male mutation bias
at different sites in the primate genomes: Insights from the
human-chimpanzee comparison. Mol. Biol. Evol. 23, 565–
573.
43. Weinberg, W. (1912). Zur Vererbung des Zwergwuchses.
Arch. Rassen-u Gesell. Biol. 9, 710–718.
44. Crow, J.F. (2006). Age and sex effects on human mutation
rates: An old problem with new complexities. J. Radiat. Res.
(Tokyo) 47 (Suppl B ), B75–B82.
45. Moloney, D.M., Slaney, S.F., Oldridge, M., Wall, S.A., Sahlin,
P., Stenman, G., and Wilkie, A.O.M. (1996). Exclusive
paternal origin of new mutations in Apert syndrome. Nat.
Genet. 13, 48–53.
46. Kondrashov, A.S. (2003). Direct estimates of human per
nucleotide mutation rates at 20 loci causing Mendelian
diseases. Hum. Mutat. 21, 12–27.
47. Nachman, M.W., and Crowell, S.L. (2000). Estimate of the
mutation rate per nucleotide in humans. Genetics 156,
297–304.10, 2012
48. Roach, J.C., Glusman, G., Smit, A.F., Huff, C.D., Hubley, R.,
Shannon, P.T., Rowen, L., Pant, K.P., Goodman, N., Bamshad,
M., et al. (2010). Analysis of genetic inheritance in a
family quartet by whole-genome sequencing. Science 328,
636–639.
49. Lynch, M. (2010). Rate, molecular spectrum, and conse-
quences of human mutation. Proc. Natl. Acad. Sci. USA
107, 961–968.
50. Durbin, R.M., Abecasis, G.R., Altshuler, D.L., Auton, A.,
Brooks, L.D., Gibbs, R.A., Hurles, M.E., and McVean, G.A.;
1000 Genomes Project Consortium. (2010). Amap of human
genome variation from population-scale sequencing. Nature
467, 1061–1073.
51. Kondrashov, F.A., and Kondrashov, A.S. (2010). Measure-
ments of spontaneous rates of mutations in the recent past
and the near future. Philos. Trans. R. Soc. Lond. B Biol. Sci.
365, 1169–1176.
52. Conrad, D.F., Keebler, J.E., DePristo, M.A., Lindsay, S.J.,
Zhang, Y., Casals, F., Idaghdour, Y., Hartl, C.L., Torroja, C.,
Garimella, K.V., et al; 1000 Genomes Project. (2011). Varia-
tion in genome-wide mutation rates within and between
human families. Nat. Genet. 43, 712–714.
53. Tiemann-Boege, I., Navidi, W., Grewal, R., Cohn, D., Eske-
nazi, B., Wyrobek, A.J., and Arnheim, N. (2002). The
observed human sperm mutation frequency cannot explain
the achondroplasia paternal age effect. Proc. Natl. Acad.
Sci. USA 99, 14952–14957.
54. Glaser, R.L., Broman, K.W., Schulman, R.L., Eskenazi, B.,
Wyrobek, A.J., and Jabs, E.W. (2003). The paternal-age effect
in Apert syndrome is due, in part, to the increased frequency
of mutations in sperm. Am. J. Hum. Genet. 73, 939–947.
55. Wilkie, A.O.M. (2005). Bad bones, absent smell, selfish testes:
The pleiotropic consequences of human FGF receptor muta-
tions. Cytokine Growth Factor Rev. 16, 187–203.
56. Goriely, A., McVean, G.A., Ro¨jmyr, M., Ingemarsson, B., and
Wilkie, A.O.M. (2003). Evidence for selective advantage of
pathogenic FGFR2 mutations in the male germ line. Science
301, 643–646.
57. Goriely, A., McVean, G.A., van Pelt, A.M., O’Rourke, A.W.,
Wall, S.A., de Rooij, D.G., and Wilkie, A.O.M. (2005). Gain-
of-function amino acid substitutions drive positive selection
of FGFR2 mutations in human spermatogonia. Proc. Natl.
Acad. Sci. USA 102, 6051–6056.
58. Yoon, S.R., Qin, J., Glaser, R.L., Jabs, E.W.,Wexler, N.S., Sokol,
R., Arnheim, N., and Calabrese, P. (2009). The ups and downs
of mutation frequencies during aging can account for
the Apert syndrome paternal age effect. PLoS Genet. 5,
e1000558.
59. Qin, J., Calabrese, P., Tiemann-Boege, I., Shinde, D.N., Yoon,
S.R., Gelfand, D., Bauer, K., and Arnheim, N. (2007). The
molecular anatomy of spontaneous germline mutations in
human testes. PLoS Biol. 5, e224.
60. Choi, S.K., Yoon, S.R., Calabrese, P., and Arnheim, N. (2008).
A germ-line-selective advantage rather than an increased
mutation rate can explain some unexpectedly common
human disease mutations. Proc. Natl. Acad. Sci. USA 105,
10143–10148.
61. Dakouane Giudicelli, M., Serazin, V., Le Sciellour, C.R.,
Albert, M., Selva, J., and Giudicelli, Y. (2008). Increased
achondroplasia mutation frequency with advanced age and
evidence for G1138A mosaicism in human testis biopsies.
Fertil. Steril. 89, 1651–1656.The America62. Goriely, A., Hansen, R.M., Taylor, I.B., Olesen, I.A., Jacobsen,
G.K., McGowan, S.J., Pfeifer, S.P., McVean, G.A., Rajpert-De
Meyts, E., and Wilkie, A.O.M. (2009). Activating mutations
in FGFR3 andHRAS reveal a shared genetic origin for congen-
ital disorders and testicular tumors. Nat. Genet. 41, 1247–
1252.
63. Tavormina, P.L., Shiang, R., Thompson, L.M., Zhu, Y.Z.,
Wilkin, D.J., Lachman, R.S., Wilcox, W.R., Rimoin, D.L.,
Cohn, D.H., and Wasmuth, J.J. (1995). Thanatophoric
dysplasia (types I and II) caused by distinct mutations in
fibroblast growth factor receptor 3. Nat. Genet. 9, 321–328.
64. Hodgkinson, A., and Eyre-Walker, A. (2010). The genomic
distribution and local context of coincident SNPs in human
and chimpanzee. Genome Biol Evol 2, 547–557.
65. Gorlov, I.P., Gorlova, O.Y., and Amos, C.I. (2008). Relative
effects of mutability and selection on single nucleotide poly-
morphisms in transcribed regions of the human genome.
BMC Genomics 9, 292.
66. Hansen, R.M.S., Goriely, A., Wall, S.A., Roberts, I.S., and
Wilkie, A.O.M. (2005). Fibroblast growth factor receptor 2,
gain-of-function mutations, and tumourigenesis: Investi-
gating a potential link. J. Pathol. 207, 27–31.
67. Eble, J.N. (1994). Spermatocytic seminoma. Hum. Pathol. 25,
1035–1042.
68. Rajpert-De Meyts, E. (2007). Recent advances and future
directions in research on testicular germ cell cancer. Int. J.
Androl. 30, 192–197.
69. Lim, J., Goriely, A., Turner, G.D., Ewen, K.A., Jacobsen, G.K.,
Graem, N., Wilkie, A.O.M., and Rajpert-De Meyts, E. (2011).
OCT2, SSX and SAGE1 reveal the phenotypic heterogeneity
of spermatocytic seminoma reflecting distinct subpopula-
tions of spermatogonia. J. Pathol. 224, 473–483.
70. Fasano, O., Aldrich, T., Tamanoi, F., Taparowsky, E., Furth,
M., and Wigler, M. (1984). Analysis of the transforming
potential of the human H-ras gene by random mutagenesis.
Proc. Natl. Acad. Sci. USA 81, 4008–4012.
71. Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H.,
Tanaka, Y., Filocamo, M., Kato, K., Suzuki, Y., Kure, S., and
Matsubara, Y. (2005). Germline mutations in HRAS proto-
oncogene cause Costello syndrome. Nat. Genet. 37, 1038–
1040.
72. Bellus, G.A., Spector, E.B., Speiser, P.W., Weaver, C.A., Garber,
A.T., Bryke, C.R., Israel, J., Rosengren, S.S.,Webster, M.K., Do-
noghue, D.J., and Francomano, C.A. (2000). Distinct
missense mutations of the FGFR3 lys650 codon modulate
receptor kinase activation and the severity of the skeletal
dysplasia phenotype. Am. J. Hum. Genet. 67, 1411–1421.
73. Berk, D.R., Spector, E.B., and Bayliss, S.J. (2007). Familial
acanthosis nigricans due to K650T FGFR3 mutation. Arch.
Dermatol. 143, 1153–1156.
74. Hafner, C., Hartmann, A., Real, F.X., Hofstaedter, F., Land-
thaler, M., and Vogt, T. (2007). Spectrum of FGFR3mutations
in multiple intraindividual seborrheic keratoses. J. Invest.
Dermatol. 127, 1883–1885.
75. Ota, S., Zhou, Z.Q., Link, J.M., and Hurlin, P.J. (2009).
The role of senescence and prosurvival signaling in control-
ling the oncogenic activity of FGFR2 mutants associated
with cancer and birth defects. Hum. Mol. Genet. 18, 2609–
2621.
76. Krejci, P., Prochazkova, J., Smutny, J., Chlebova, K., Lin, P.,
Aklian, A., Bryja, V., Kozubik, A., and Wilcox, W.R. (2010).
FGFR3 signaling induces a reversible senescence phenotypen Journal of Human Genetics 90, 175–200, February 10, 2012 195
in chondrocytes similar to oncogene-induced premature
senescence. Bone 47, 102–110.
77. Vogelstein, B., and Kinzler, K.W. (2004). Cancer genes and
the pathways they control. Nat. Med. 10, 789–799.
78. Nowell, P.C. (2002). Tumor progression: A brief historical
perspective. Semin. Cancer Biol. 12, 261–266.
79. Miyauchi, A., Futami, H., Hai, N., Yokozawa, T., Kuma, K.,
Aoki, N., Kosugi, S., Sugano, K., and Yamaguchi, K. (1999).
Two germline missense mutations at codons 804 and 806
of the RET proto-oncogene in the same allele in a patient
with multiple endocrine neoplasia type 2B without codon
918 mutation. Jpn. J. Cancer Res. 90, 1–5.
80. Iwashita, T., Murakami, H., Kurokawa, K., Kawai, K., Miyau-
chi, A., Futami, H., Qiao, S., Ichihara, M., and Takahashi,
M. (2000). A two-hit model for development of multiple
endocrine neoplasia type 2B by RET mutations. Biochem.
Biophys. Res. Commun. 268, 804–808.
81. Shukla, V., Coumoul, X., Wang, R.H., Kim, H.S., and Deng,
C.X. (2007). RNA interference and inhibition of MEK-ERK
signaling prevent abnormal skeletal phenotypes in a mouse
model of craniosynostosis. Nat. Genet. 39, 1145–1150.
82. Chen, P.C., Wakimoto, H., Conner, D., Araki, T., Yuan, T.,
Roberts, A., Seidman, C.E., Bronson, R., Neel, B.G., Seidman,
J.G., and Kucherlapati, R. (2010). Activation of multiple
signaling pathways causes developmental defects in mice
with a Noonan syndrome–associated Sos1 mutation. J.
Clin. Invest. 120, 4353–4365.
83. Wu, X., Simpson, J., Hong, J.H., Kim, K.H., Thavarajah, N.K.,
Backx, P.H., Neel, B.G., and Araki, T. (2011). MEK-ERK
pathway modulation ameliorates disease phenotypes in
a mouse model of Noonan syndrome associated with the
Raf1(L613V) mutation. J. Clin. Invest. 121, 1009–1025.
84. Krenz, M., Yutzey, K.E., and Robbins, J. (2005). Noonan
syndrome mutation Q79R in Shp2 increases proliferation
of valve primordia mesenchymal cells via extracellular
signal-regulated kinase 1/2 signaling. Circ. Res. 97, 813–820.
85. Rosenberger, G., Meien, S., and Kutsche, K. (2009). Onco-
genic HRAS mutations cause prolonged PI3K signaling in
response to epidermal growth factor in fibroblasts of patients
with Costello syndrome. Hum. Mutat. 30, 352–362.
86. Cancilla, B., Davies, A., Ford-Perriss, M., and Risbridger, G.P.
(2000). Discrete cell- and stage-specific localisation of fibro-
blast growth factors and receptor expression during testis
development. J. Endocrinol. 164, 149–159.
87. vonKopylow,K., Kirchhoff, C., Jezek,D., Schulze,W., Feig,C.,
Primig, M., Steinkraus, V., and Spiess, A.N. (2010). Screening
for biomarkers of spermatogonia within the human testis: A
whole genome approach. Hum. Reprod. 25, 1104–1112.
88. Krajewska, M., Banares, S., Zhang, E.E., Huang, X., Scadeng,
M., Jhala, U.S., Feng, G.S., and Krajewski, S. (2008). Develop-
ment of diabesity in mice with neuronal deletion of Shp2
tyrosine phosphatase. Am. J. Pathol. 172, 1312–1324.
89. Hermo, L., Pelletier, R.M., Cyr, D.G., and Smith, C.E. (2010).
Surfing the wave, cycle, life history, and genes/proteins ex-
pressed by testicular germ cells. Part 5: Intercellular junctions
and contacts between germs cells and Sertoli cells and their
regulatory interactions, testicular cholesterol, and genes/
proteins associated withmore than one germ cell generation.
Microsc. Res. Tech. 73, 409–494.
90. Naughton, C.K., Jain, S., Strickland, A.M., Gupta, A., and
Milbrandt, J. (2006). Glial cell-line derived neurotrophic196 The American Journal of Human Genetics 90, 175–200, Februaryfactor-mediated RET signaling regulates spermatogonial
stem cell fate. Biol. Reprod. 74, 314–321.
91. Meng, X., Lindahl, M., Hyvo¨nen, M.E., Parvinen, M., de
Rooij, D.G., Hess, M.W., Raatikainen-Ahokas, A., Sainio, K.,
Rauvala, H., Lakso, M., et al. (2000). Regulation of cell fate
decision of undifferentiated spermatogonia by GDNF.
Science 287, 1489–1493.
92. Meng, X., de Rooij, D.G., Westerdahl, K., Saarma, M., and
Sariola, H. (2001). Promotion of seminomatous tumors by
targeted overexpression of glial cell line-derived neurotro-
phic factor in mouse testis. Cancer Res. 61, 3267–3271.
93. Kubota, H., Avarbock, M.R., and Brinster, R.L. (2004).
Growth factors essential for self-renewal and expansion of
mouse spermatogonial stem cells. Proc. Natl. Acad. Sci. USA
101, 16489–16494.
94. Brinster, R.L., and Zimmermann, J.W. (1994). Spermatogen-
esis following male germ-cell transplantation. Proc. Natl.
Acad. Sci. USA 91, 11298–11302.
95. Oatley, J.M., Avarbock, M.R., and Brinster, R.L. (2007). Glial
cell line-derived neurotrophic factor regulation of genes
essential for self-renewal of mouse spermatogonial stem cells
is dependent on Src family kinase signaling. J. Biol. Chem.
282, 25842–25851.
96. Lee, J., Kanatsu-Shinohara, M., Inoue, K., Ogonuki, N., Miki,
H., Toyokuni, S., Kimura, T., Nakano, T., Ogura, A., and
Shinohara, T. (2007). Akt mediates self-renewal division of
mouse spermatogonial stem cells. Development 134, 1853–
1859.
97. Lee, J., Kanatsu-Shinohara, M., Morimoto, H., Kazuki, Y., Ta-
kashima, S., Oshimura, M., Toyokuni, S., and Shinohara, T.
(2009). Genetic reconstruction of mouse spermatogonial
stem cell self-renewal in vitro by Ras-cyclin D2 activation.
Cell Stem Cell 5, 76–86.
98. Nakagawa, T., Nabeshima, Y., and Yoshida, S. (2007). Func-
tional identification of the actual and potential stem cell
compartments in mouse spermatogenesis. Dev. Cell 12,
195–206.
99. Klein, A.M., Nakagawa, T., Ichikawa, R., Yoshida, S., and
Simons, B.D. (2010). Mouse germ line stem cells undergo
rapid and stochastic turnover. Cell Stem Cell 7, 214–224.
100. He, Z., Kokkinaki, M., Jiang, J., Dobrinski, I., and Dym, M.
(2010). Isolation, characterization, and culture of human
spermatogonia. Biol. Reprod. 82, 363–372.
101. Moreno, E. (2008). Is cell competition relevant to cancer?
Nat. Rev. Cancer 8, 141–147.
102. Nielsen, R., Bustamante, C., Clark, A.G., Glanowski, S., Sack-
ton, T.B., Hubisz, M.J., Fledel-Alon, A., Tanenbaum, D.M.,
Civello, D., White, T.J., et al. (2005). A scan for positively
selected genes in the genomes of humans and chimpanzees.
PLoS Biol. 3, e170.
103. Khaitovich, P., Enard, W., Lachmann, M., and Pa¨a¨bo, S.
(2006). Evolution of primate gene expression. Nat. Rev.
Genet. 7, 693–702.
104. McGowan, K.A., Li, J.Z., Park, C.Y., Beaudry, V., Tabor, H.K.,
Sabnis, A.J., Zhang, W., Fuchs, H., de Angelis, M.H., Myers,
R.M., et al. (2008). Ribosomal mutations cause p53-mediated
dark skin and pleiotropic effects. Nat. Genet. 40, 963–970.
105. Emison, E.S., McCallion, A.S., Kashuk, C.S., Bush, R.T., Grice,
E., Lin, S., Portnoy, M.E., Cutler, D.J., Green, E.D., and Chak-
ravarti, A. (2005). A common sex-dependent mutation in
a RET enhancer underlies Hirschsprung disease risk. Nature
434, 857–863.10, 2012
106. De Gobbi, M., Viprakasit, V., Hughes, J.R., Fisher, C., Buckle,
V.J., Ayyub, H., Gibbons, R.J., Vernimmen, D., Yoshinaga, Y.,
de Jong, P., et al. (2006). A regulatory SNP causes a human
genetic disease by creating a new transcriptional promoter.
Science 312, 1215–1217.
107. To, M.D., Perez-Losada, J., Mao, J.H., Hsu, J., Jacks, T., and
Balmain, A. (2006). A functional switch from lung cancer
resistance to susceptibility at the Pas1 locus in Kras2LA2
mice. Nat. Genet. 38, 926–930.
108. Moreno, E., and Basler, K. (2004). dMyc transforms cells into
super-competitors. Cell 117, 117–129.
109. Zhang, F., Gu, W., Hurles, M.E., and Lupski, J.R. (2009). Copy
number variation in human health, disease, and evolution.
Annu. Rev. Genomics Hum. Genet. 10, 451–481.
110. Lupski, J.R., and Stankiewicz, P. (2005). Genomic disorders:
Molecular mechanisms for rearrangements and conveyed
phenotypes. PLoS Genet. 1, e49.
111. Hastings, P.J., Lupski, J.R., Rosenberg, S.M., and Ira, G.
(2009). Mechanisms of change in gene copy number. Nat.
Rev. Genet. 10, 551–564.
112. Turner, D.J., Miretti, M., Rajan, D., Fiegler, H., Carter, N.P.,
Blayney, M.L., Beck, S., and Hurles, M.E. (2008). Germline
rates of de novo meiotic deletions and duplications causing
several genomic disorders. Nat. Genet. 40, 90–95.
113. Lee, J.A., Carvalho, C.M., and Lupski, J.R. (2007). A DNA
replication mechanism for generating nonrecurrent rear-
rangements associated with genomic disorders. Cell 131,
1235–1247.
114. Arlt, M.F., Mulle, J.G., Schaibley, V.M., Ragland, R.L., Durkin,
S.G., Warren, S.T., and Glover, T.W. (2009). Replication stress
induces genome-wide copy number changes in human cells
that resemble polymorphic and pathogenic variants. Am. J.
Hum. Genet. 84, 339–350.
115. Zhang, F., Seeman, P., Liu, P., Weterman,M.A., Gonzaga-Jaur-
egui, C., Towne, C.F., Batish, S.D., De Vriendt, E., De Jonghe,
P., Rautenstrauss, B., et al. (2010). Mechanisms for nonrecur-
rent genomic rearrangements associated with CMT1A or
HNPP: Rare CNVs as a cause for missing heritability. Am. J.
Hum. Genet. 86, 892–903.
116. Hehir-Kwa, J.Y., Rodrı´guez-Santiago, B., Vissers, L.E., de
Leeuw, N., Pfundt, R., Buitelaar, J.K., Pe´rez-Jurado, L.A., and
Veltman, J.A. (2011). De novo copy number variants associ-
ated with intellectual disability have a paternal origin and
age bias. J. Med. Genet. 48, 776–778.
117. Itsara, A., Wu, H., Smith, J.D., Nickerson, D.A., Romieu, I.,
London, S.J., and Eichler, E.E. (2010). De novo rates and
selection of large copy number variation. Genome Res. 20,
1469–1481.
118. Thomas, N.S., Morris, J.K., Baptista, J., Ng, B.L., Crolla, J.A.,
and Jacobs, P.A. (2010). De novo apparently balanced trans-
locations in man are predominantly paternal in origin and
associated with a significant increase in paternal age. J.
Med. Genet. 47, 112–115.
119. Krab, L.C., Goorden, S.M., and Elgersma, Y. (2008). Onco-
genes on my mind: ERK and MTOR signaling in cognitive
diseases. Trends Genet. 24, 498–510.
120. Samuels, I.S., Saitta, S.C., and Landreth, G.E. (2009). MAP’-
ing CNS development and cognition: An ERKsome process.
Neuron 61, 160–167.
121. Malaspina, D., Corcoran, C., Fahim, C., Berman, A., Harkavy-
Friedman, J., Yale, S., Goetz, D., Goetz, R., Harlap, S., and
Gorman, J. (2002). Paternal age and sporadic schizophrenia:The AmericaEvidence for de novo mutations. Am. J. Med. Genet. 114,
299–303.
122. Byrne, M., Agerbo, E., Ewald, H., Eaton, W.W., and Morten-
sen, P.B. (2003). Parental age and risk of schizophrenia: A
case-control study. Arch. Gen. Psychiatry 60, 673–678.
123. Tsuchiya, K.J., Matsumoto, K., Miyachi, T., Tsujii, M., Naka-
mura, K., Takagai, S., Kawai, M., Yagi, A., Iwaki, K., Suda, S.,
et al. (2008). Paternal age at birth and high-functioning
autistic-spectrum disorder in offspring. Br. J. Psychiatry
193, 316–321.
124. Durkin, M.S., Maenner, M.J., Newschaffer, C.J., Lee, L.C.,
Cunniff, C.M., Daniels, J.L., Kirby, R.S., Leavitt, L., Miller,
L., Zahorodny, W., and Schieve, L.A. (2008). Advanced
parental age and the risk of autism spectrum disorder. Am.
J. Epidemiol. 168, 1268–1276.
125. Vissers, L.E., de Ligt, J., Gilissen, C., Janssen, I., Steehouwer,
M., de Vries, P., van Lier, B., Arts, P., Wieskamp, N., del Ro-
sario, M., et al. (2010). A de novo paradigm for mental retar-
dation. Nat. Genet. 42, 1109–1112.
126. Pinto,D., Pagnamenta,A.T., Klei, L., Anney,R.,Merico,D., Re-
gan, R., Conroy, J., Magalhaes, T.R., Correia, C., Abrahams,
B.S., et al. (2010). Functional impact of global rare copy
number variation in autism spectrum disorders. Nature 466,
368–372.
127. O’Roak, B.J., Deriziotis, P., Lee, C., Vives, L., Schwartz, J.J.,
Girirajan, S., Karakoc, E., Mackenzie, A.P., Ng, S.B., Baker,
C., et al. (2011). Exome sequencing in sporadic autism spec-
trum disorders identifies severe de novo mutations. Nat.
Genet. 43, 585–589.
128. Levy, D., Ronemus, M., Yamrom, B., Lee, Y.H., Leotta, A.,
Kendall, J., Marks, S., Lakshmi, B., Pai, D., Ye, K., et al.
(2011). Rare de novo and transmitted copy-number variation
in autistic spectrum disorders. Neuron 70, 886–897.
129. Xu, B., Roos, J.L., Levy, S., van Rensburg, E.J., Gogos, J.A., and
Karayiorgou, M. (2008). Strong association of de novo copy
number mutations with sporadic schizophrenia. Nat. Genet.
40, 880–885.
130. Awadalla, P., Gauthier, J., Myers, R.A., Casals, F., Hamdan,
F.F., Griffing, A.R., Coˆte´, M., Henrion, E., Spiegelman, D.,
Tarabeux, J., et al. (2010). Direct measure of the de novo
mutation rate in autism and schizophrenia cohorts. Am. J.
Hum. Genet. 87, 316–324.
131. Girard, S.L., Gauthier, J., Noreau, A., Xiong, L., Zhou, S.,
Jouan, L., Dionne-Laporte, A., Spiegelman, D., Henrion, E.,
Diallo, O., et al. (2011). Increased exonic de novo mutation
rate in individuals with schizophrenia. Nat. Genet. 43,
860–863.
132. Xu, B., Roos, J.L., Dexheimer, P., Boone, B., Plummer, B.,
Levy, S., Gogos, J.A., and Karayiorgou, M. (2011). Exome
sequencing supports a de novo mutational paradigm for
schizophrenia. Nat. Genet. 43, 864–868.
133. Girirajan, S., Rosenfeld, J.A., Cooper, G.M., Antonacci, F., Sis-
wara, P., Itsara, A., Vives, L., Walsh, T., McCarthy, S.E., Baker,
C., et al. (2010). A recurrent 16p12.1 microdeletion supports
a two-hit model for severe developmental delay. Nat. Genet.
42, 203–209.
134. Gilman, S.R., Iossifov, I., Levy, D., Ronemus, M., Wigler, M.,
and Vitkup, D. (2011). Rare de novo variants associated with
autism implicate a large functional networkof genes involved
in formation and function of synapses. Neuron 70, 898–907.
135. Klejbor, I., Myers, J.M., Hausknecht, K., Corso, T.D., Gam-
bino, A.S., Morys, J., Maher, P.A., Hard, R., Richards, J.,n Journal of Human Genetics 90, 175–200, February 10, 2012 197
Stachowiak, E.K., and Stachowiak, M.K. (2006). Fibroblast
growth factor receptor signaling affects development
and function of dopamine neurons - inhibition results in
a schizophrenia-like syndrome in transgenic mice. J. Neuro-
chem. 97, 1243–1258.
136. Kalkman, H.O. (2006). The role of the phosphatidylinositide
3-kinase-protein kinase B pathway in schizophrenia. Phar-
macol. Ther. 110, 117–134.
137. Kim, J.Y., Duan, X., Liu, C.Y., Jang, M.H., Guo, J.U., Pow-an-
pongkul, N., Kang, E., Song, H., and Ming, G.L. (2009).
DISC1 regulates new neuron development in the adult brain
via modulation of AKT-mTOR signaling through KIAA1212.
Neuron 63, 761–773.
138. Ke´ri, S., Seres, I., Kelemen, O., and Benedek, G. (2009).
Neuregulin 1-stimulated phosphorylation of AKT in
psychotic disorders and its relationship with neurocognitive
functions. Neurochem. Int. 55, 606–609.
139. Goriely, A., and Wilkie, A.O.M. (2010). Missing heritability:
Paternal age effect mutations and selfish spermatogonia.
Nat. Rev. Genet. 11, 589.
140. Juul, A., Aksglaede, L., Lund, A.M., Duno, M., Skakkebaek,
N.E., and Rajpert-De Meyts, E. (2007). Preserved fertility in
a non-mosaic Klinefelter patient with a mutation in the
fibroblast growth factor receptor 3 gene: Case report. Hum.
Reprod. 22, 1907–1911.
141. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D.,
Thompson, D., Ballinger, D.G., Struewing, J.P., Morrison, J.,
Field, H., Luben, R., et al; SEARCH collaborators; kConFab;
AOCS Management Group. (2007). Genome-wide associa-
tion study identifies novel breast cancer susceptibility loci.
Nature 447, 1087–1093.
142. Hunter, D.J., Kraft, P., Jacobs, K.B., Cox, D.G., Yeager, M.,
Hankinson, S.E., Wacholder, S., Wang, Z., Welch, R., Hutch-
inson, A., et al. (2007). A genome-wide association study
identifies alleles in FGFR2 associated with risk of sporadic
postmenopausal breast cancer. Nat. Genet. 39, 870–874.
143. O’Donovan, M.C., Norton, N., Williams, H., Peirce, T., Mosk-
vina, V., Nikolov, I., Hamshere, M., Carroll, L., Georgieva, L.,
Dwyer, S., et al; Molecular Genetics of Schizophrenia Collab-
oration. (2009). Analysis of 10 independent samples
provides evidence for association between schizophrenia
and a SNP flanking fibroblast growth factor receptor 2.
Mol. Psychiatry 14, 30–36.
144. Shi, Y., Li, Z., Xu, Q., Wang, T., Li, T., Shen, J., Zhang, F.,
Chen, J., Zhou, G., Ji, W., et al. (2011). Common variants
on 8p12 and 1q24.2 confer risk of schizophrenia. Nat. Genet.
43, 1224–1227.
145. Kiemeney, L.A., Sulem, P., Besenbacher, S., Vermeulen, S.H.,
Sigurdsson, A., Thorleifsson, G., Gudbjartsson, D.F., Stacey,
S.N., Gudmundsson, J., Zanon, C., et al. (2010). A sequence
variant at 4p16.3 confers susceptibility to urinary bladder
cancer. Nat. Genet. 42, 415–419.
146. Johne, A., Roots, I., and Brockmo¨ller, J. (2003). A single
nucleotide polymorphism in the human H-ras proto-onco-
gene determines the risk of urinary bladder cancer. Cancer
Epidemiol. Biomarkers Prev. 12, 68–70.
147. Sathyan, K.M., Nalinakumari, K.R., Abraham, T., and
Kannan, S. (2006). Influence of single nucleotide polymor-
phisms in H-Ras and cyclin D1 genes on oral cancer suscep-
tibility. Oral Oncol. 42, 607–613.
148. Zhang, Y., Jin, M., Liu, B., Ma, X., Yao, K., Li, Q., and Chen, K.
(2008). Association between H-RAS T81C genetic polymor-198 The American Journal of Human Genetics 90, 175–200, Februaryphism and gastrointestinal cancer risk: A population based
case-control study in China. BMC Cancer 8, 256.
149. Crespi, B., Summers, K., and Dorus, S. (2007). Adaptive
evolution of genes underlying schizophrenia. Proc. Biol.
Sci. 274, 2801–2810.
150. Lappalainen, T., Salmela, E., Andersen, P.M., Dahlman-
Wright, K., Sistonen, P., Savontaus, M.L., Schreiber, S., La-
hermo, P., and Kere, J. (2010). Genomic landscape of positive
natural selection in Northern European populations. Eur. J.
Hum. Genet. 18, 471–478.
151. Dorus, S., Vallender, E.J., Evans, P.D., Anderson, J.R., Gilbert,
S.L., Mahowald, M., Wyckoff, G.J., Malcom, C.M., and Lahn,
B.T. (2004). Accelerated evolution of nervous system genes in
the origin of Homo sapiens. Cell 119, 1027–1040.
152. Gripp, K.W., Stabley, D.L., Nicholson, L., Hoffman, J.D., and
Sol-Church, K. (2006). Somatic mosaicism for an HRAS
mutation causes Costello syndrome. Am. J. Med. Genet. A.
140, 2163–2169.
153. Goriely, A., Lord, H., Lim, J., Johnson, D., Lester, T., Firth,
H.V., and Wilkie, A.O.M. (2010). Germline and somatic
mosaicism for FGFR2 mutation in the mother of a child
with Crouzon syndrome: Implications for genetic testing in
‘‘paternal age-effect’’ syndromes. Am. J. Med. Genet. A.
152A, 2067–2073.
154. Tang, D.L., Li, Y., Zhou, X., Li, X., and Zheng, F. (2009).
Multiplex fluorescent PCR for noninvasive prenatal detec-
tion of fetal-derived paternally inherited diseases using circu-
latory fetal DNA in maternal plasma. Eur. J. Obstet. Gynecol.
Reprod. Biol. 144, 35–39.
155. Chitty, L.S., Griffin, D.R., Meaney, C., Barrett, A., Khalil, A.,
Pajkrt, E., and Cole, T.J. (2011). New aids for the non-inva-
sive prenatal diagnosis of achondroplasia: Dysmorphic
features, charts of fetal size and molecular confirmation
using cell-free fetal DNA in maternal plasma. Ultrasound
Obstet. Gynecol. 37, 283–289.
156. Lim, J.H., Kim, M.J., Kim, S.Y., Kim, H.O., Song, M.J., Kim,
M.H., Park, S.Y., Yang, J.H., and Ryu, H.M. (2011). Non-inva-
sive prenatal detection of achondroplasia using circulating
fetal DNA in maternal plasma. J. Assist. Reprod. Genet. 28,
167–172.
157. Eid, J., Fehr, A., Gray, J., Luong, K., Lyle, J., Otto, G., Peluso,
P., Rank, D., Baybayan, P., Bettman, B., et al. (2009). Real-
time DNA sequencing from single polymerase molecules.
Science 323, 133–138.
158. Fan, H.C., Wang, J., Potanina, A., and Quake, S.R. (2011).
Whole-genome molecular haplotyping of single cells. Nat.
Biotechnol. 29, 51–57.
159. Kalisky, T., and Quake, S.R. (2011). Single-cell genomics. Nat.
Methods 8, 311–314.
160. Chen, Z., Feng, J., Buzin, C.H., Liu, Q., Weiss, L., Kernstine,
K., Somlo, G., and Sommer, S.S. (2009). Analysis of cancer
mutation signatures in blood by a novel ultra-sensitive assay:
Monitoring of therapy or recurrence in non-metastatic breast
cancer. PLoS ONE 4, e7220.
161. Hansen, R.M.S. (2006). Fibroblast growth factor receptor 2
mutations in human sperm: Biological implications. DPhil
thesis, University of Oxford, Oxford, UK.
162. Glaser, R.L., Jiang, W., Boyadjiev, S.A., Tran, A.K., Zachary,
A.A., Van Maldergem, L., Johnson, D., Walsh, S., Oldridge,
M., Wall, S.A., et al. (2000). Paternal origin of FGFR2 muta-
tions in sporadic cases of Crouzon syndrome and Pfeiffer
syndrome. Am. J. Hum. Genet. 66, 768–777.10, 2012
163. Wilkin, D.J., Szabo, J.K., Cameron, R., Henderson, S., Bellus,
G.A., Mack, M.L., Kaitila, I., Loughlin, J., Munnich, A., Sykes,
B., et al. (1998). Mutations in fibroblast growth-factor
receptor 3 in sporadic cases of achondroplasia occur exclu-
sively on the paternally derived chromosome. Am. J. Hum.
Genet. 63, 711–716.
164. Søvik, O., Schubbert, S., Houge, G., Steine, S.J., Norga˚rd, G.,
Engelsen, B., Njølstad, P.R., Shannon, K., and Molven, A.
(2007). De novo HRAS and KRAS mutations in two siblings
with short stature and neuro-cardio-facio-cutaneous
features. J. Med. Genet. 44, e84.
165. Gripp, K.W., Hopkins, E., Sol-Church, K., Stabley, D.L., Axel-
rad, M.E., Doyle, D., Dobyns, W.B., Hudson, C., Johnson, J.,
Tenconi, R., et al. (2011). Phenotypic analysis of individuals
with Costello syndrome due to HRAS p.G13C. Am. J. Med.
Genet. A. 155A, 706–716.
166. Wohllk, N., Cote, G.J., Bugalho, M.M., Ordonez, N., Evans,
D.B., Goepfert, H., Khorana, S., Schultz, P., Richards, C.S.,
and Gagel, R.F. (1996). Relevance of RET proto-oncogene
mutations in sporadic medullary thyroid carcinoma. J.
Clin. Endocrinol. Metab. 81, 3740–3745.
167. Mulligan, L.M., Eng, C., Healey, C.S., Clayton, D., Kwok, J.B.,
Gardner, E., Ponder, M.A., Frilling, A., Jackson, C.E., Lehnert,
H., et al. (1994). Specific mutations of the RET proto-onco-
gene are related to disease phenotype in MEN 2A and
FMTC. Nat. Genet. 6, 70–74.
168. Kitamura, Y., Scavarda, N., Wells, S.A., Jr., Jackson, C.E., and
Goodfellow, P.J. (1995). Two maternally derived missense
mutations in the tyrosine kinase domain of the RET protoon-
cogene in a patient with de novoMEN 2B. Hum.Mol. Genet.
4, 1987–1988.
169. Sharland, M., Burch, M., McKenna, W.M., and Paton, M.A.
(1992). A clinical study of Noonan syndrome. Arch. Dis.
Child. 67, 178–183.
170. Li, R., Johnson, A.B., Salomons, G.S., van der Knaap, M.S.,
Rodriguez, D., Boespflug-Tanguy, O., Gorospe, J.R., Gold-
man, J.E., Messing, A., and Brenner, M. (2006). Propensity
for paternal inheritance of de novo mutations in Alexander
disease. Hum. Genet. 119, 137–144.
171. Pauli, S., von Velsen, N., Burfeind, P., Steckel, M., Ma¨nz, J.,
Buchholz, A., Borozdin, W., and Kohlhase, J. (2012). CHD7
mutations causing CHARGE syndrome are predominantly
of paternal origin. Clin. Genet. 81, 234–239.
172. Twigg, S.R.F., Matsumoto, K., Kidd, A.M., Goriely, A., Taylor,
I.B., Fisher, R.B., Hoogeboom, A.J., Mathijssen, I.M., Lour-
enco, M.T., Morton, J.E., et al. (2006). The origin of EFNB1
mutations in craniofrontonasal syndrome: Frequent somatic
mosaicism and explanation of the paucity of carrier males.
Am. J. Hum. Genet. 78, 999–1010.
173. Heron, S.E., Scheffer, I.E., Iona, X., Zuberi, S.M., Birch, R.,
McMahon, J.M., Bruce, C.M., Berkovic, S.F., and Mulley,
J.C. (2010). De novo SCN1A mutations in Dravet syndrome
and related epileptic encephalopathies are largely of paternal
origin. J. Med. Genet. 47, 137–141.
174. Sun, H., Zhang, Y., Liu, X., Ma, X., Yang, Z., Qin, J., Jiang, Y.,
Qi, Y., and Wu, X. (2010). Analysis of SCN1A mutation and
parental origin in patients with Dravet syndrome. J. Hum.
Genet. 55, 421–427.
175. Trappe, R., Laccone, F., Cobilanschi, J., Meins, M., Huppke,
P., Hanefeld, F., and Engel, W. (2001). MECP2 mutations in
sporadic cases of Rett syndrome are almost exclusively of
paternal origin. Am. J. Hum. Genet. 68, 1093–1101.The America176. Girard, M., Couvert, P., Carrie´, A., Tardieu, M., Chelly, J.,
Beldjord, C., and Bienvenu, T. (2001). Parental origin of de
novo MECP2 mutations in Rett syndrome. Eur. J. Hum.
Genet. 9, 231–236.
177. Zhu, X., Li, M., Pan, H., Bao, X., Zhang, J., andWu, X. (2010).
Analysis of the parental origin of de novo MECP2 mutations
and X chromosome inactivation in 24 sporadic patients with
Rett syndrome in China. J. Child Neurol. 25, 842–848.
178. Bo¨hm, J., Munk-Schulenburg, S., Felscher, S., and Kohlhase, J.
(2006). SALL1 mutations in sporadic Townes-Brocks syn-
drome are of predominantly paternal origin without obvious
paternal age effect. Am. J. Med. Genet. A. 140, 1904–1908.
179. Splendore, A., Jabs, E.W., Fe´lix, T.M., and Passos-Bueno, M.R.
(2003). Parental origin of mutations in sporadic cases of
Treacher Collins syndrome. Eur. J. Hum. Genet. 11, 718–722.
180. Ibrahimi, O.A., Yeh, B.K., Eliseenkova, A.V., Zhang, F., Olsen,
S.K., Igarashi, M., Aaronson, S.A., Linhardt, R.J., and
Mohammadi, M. (2005). Analysis of mutations in fibroblast
growth factor (FGF) and a pathogenic mutation in FGF
receptor (FGFR) provides direct evidence for the symmetric
two-end model for FGFR dimerization. Mol. Cell. Biol. 25,
671–684.
181. Lajeunie, E., Cameron, R., El Ghouzzi, V., de Parseval, N.,
Journeau, P., Gonzales, M., Delezoide, A.L., Bonaventure, J.,
Le Merrer, M., and Renier, D. (1999). Clinical variability in
patients with Apert’s syndrome. J. Neurosurg. 90, 443–447.
182. Oldridge, M., Lunt, P.W., Zackai, E.H., McDonald-McGinn,
D.M., Muenke, M., Moloney, D.M., Twigg, S.R.F., Heath,
J.K., Howard, T.D., Hoganson, G., et al. (1997). Genotype-
phenotype correlation for nucleotide substitutions in the
IgII-IgIII linker of FGFR2. Hum. Mol. Genet. 6, 137–143.
183. Wilkie, A.O.M., Patey, S.J., Kan, S.H., van den Ouweland,
A.M., and Hamel, B.C. (2002). FGFs, their receptors, and
human limb malformations: Clinical and molecular correla-
tions. Am. J. Med. Genet. 112, 266–278.
184. Ibrahimi, O.A., Zhang, F., Eliseenkova, A.V., Itoh, N., Lin-
hardt, R.J., and Mohammadi, M. (2004). Biochemical anal-
ysis of pathogenic ligand-dependent FGFR2 mutations
suggests distinct pathophysiological mechanisms for cranio-
facial and limb abnormalities. Hum. Mol. Genet. 13, 2313–
2324.
185. Cornejo-Roldan, L.R., Roessler, E., and Muenke, M. (1999).
Analysis of the mutational spectrum of the FGFR2 gene in
Pfeiffer syndrome. Hum. Genet. 104, 425–431.
186. Rump, P., Letteboer, T.G., Gille, J.J., Torringa, M.J., Baerts, W.,
van Gestel, J.P., Verheij, J.B., and van Essen, A.J. (2006).
Severe complications in a child with achondroplasia and
two FGFR3 mutations on the same allele. Am. J. Med. Genet.
A. 140, 284–290.
187. Santos, H.G., Almeida,M., Fernandes, H., andWilkie, A.O.M.
(2007). Clinical hypochondroplasia in a family caused by
a heterozygous double mutation in FGFR3 encoding
GLY380LYS. Am. J. Med. Genet. A. 143, 355–359.
188. Pannier, S., Martinovic, J., Heuertz, S., Delezoide, A.L., Mun-
nich, A., Schibler, L., Serre, V., and Legeai-Mallet, L. (2009).
Thanatophoric dysplasia caused by double missense FGFR3
mutations. Am. J. Med. Genet. A. 149A, 1296–1301.
189. Kerr, B., Delrue, M.A., Sigaudy, S., Perveen, R., Marche, M.,
Burgelin, I., Stef, M., Tang, B., Eden, O.B., O’Sullivan, J.,
et al. (2006). Genotype-phenotype correlation in Costello
syndrome: HRAS mutation analysis in 43 cases. J. Med.
Genet. 43, 401–405.n Journal of Human Genetics 90, 175–200, February 10, 2012 199
190. van der Burgt, I., Kupsky, W., Stassou, S., Nadroo, A., Barroso,
C., Diem, A., Kratz, C.P., Dvorsky, R., Ahmadian, M.R., and
Zenker, M. (2007). Myopathy caused by HRAS germline
mutations: Implications for disturbed myogenic differentia-
tion in the presence of constitutive HRas activation. J.
Med. Genet. 44, 459–462.
191. Mulligan, L.M., Kwok, J.B., Healey, C.S., Elsdon,M.J., Eng, C.,
Gardner, E., Love, D.R., Mole, S.E., Moore, J.K., Papi, L., et al.
(1993). Germ-line mutations of the RET proto-oncogene in
multiple endocrine neoplasia type 2A. Nature 363, 458–460.
192. Lips, C.J., Landsvater, R.M., Ho¨ppener, J.W., Geerdink, R.A.,
Blijham, G., van Veen, J.M., van Gils, A.P., de Wit, M.J., Ze-
wald, R.A., Berends, M.J., et al. (1994). Clinical screening as
compared with DNA analysis in families withmultiple endo-
crine neoplasia type 2A. N. Engl. J. Med. 331, 828–835.
193. Kasprzak, L., Nolet, S., Gaboury, L., Pavia, C., Villabona, C.,
Rivera-Fillat, F., Oriola, J., and Foulkes, W.D. (2001). Familial
medullary thyroid carcinoma and prominent corneal nerves
associated with the germline V804M and V778I mutations
on the same allele of RET. J. Med. Genet. 38, 784–787.
194. Bartsch, D.K., Hasse, C., Schug, C., Barth, P., Rothmund, M.,
and Ho¨ppner, W. (2000). A RET double mutation in the200 The American Journal of Human Genetics 90, 175–200, Februarygermline of a kindred with FMTC. Exp. Clin. Endocrinol.
Diabetes 108, 128–132.
195. Menko, F.H., van der Luijt, R.B., de Valk, I.A., Toorians, A.W.,
Sepers, J.M., van Diest, P.J., and Lips, C.J. (2002). Atypical
MEN type 2B associated with two germline RET mutations
on the same allele not involving codon 918. J. Clin. Endocri-
nol. Metab. 87, 393–397.
196. Gimm, O., Marsh, D.J., Andrew, S.D., Frilling, A., Dahia, P.L.,
Mulligan, L.M., Zajac, J.D., Robinson, B.G., and Eng, C.
(1997). Germline dinucleotide mutation in codon 883 of
the RET proto-oncogene in multiple endocrine neoplasia
type 2B without codon 918 mutation. J. Clin. Endocrinol.
Metab. 82, 3902–3904.
197. Smith, D.P., Houghton, C., and Ponder, B.A. (1997). Germ-
line mutation of RET codon 883 in two cases of de novo
MEN 2B. Oncogene 15, 1213–1217.
198. Jasim, S., Ying, A.K., Waguespack, S.G., Rich, T.A., Grubbs,
E.G., Jimenez, C., Hu, M.I., Cote, G., and Habra, M.A.
(2011). Multiple endocrine neoplasia type 2B with a RET
proto-oncogene A883F mutation displays a more indolent
form of medullary thyroid carcinoma compared with a RET
M918T mutation. Thyroid 21, 189–192.10, 2012
